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Allele 9.3 at TH01 injected_ multiple times on different 310's 
2 s I 6 I I I a I g I 10 I 11 I 12 
Instrument 1 
Size 186_25 186.2 
1602 1703'. 1eao;f .\sra.1.<1aitr, 
186.25 I 186.23 I 186.13 
Instrument 2 
Size 186.41 
Height 1265 
Instrument 3 
Size 186.4 
Height . 1343' 
Instrument 4 
Instrument 5 
Height 
Allele 9.3 at THO1 injected ten times with the block sitting for 2.5 hours (brand new set-up); injections 1-40 
1 2 3 4 5 6 7 8 9 ,0 µ (1 
I Size 186.39 186.38 186.36 186.39 186.44 186_38 186.35 186.4 186.44 186.29 186 0_04 Instrument 1 I Height '19~' 1932 l::1900. .'J&7~. •11199, .\1926 1967 192~, 19$7; J6?0 ,1933 42.09 
Allele 9.3 at THO1 injected ten times with the block sitting for 1 week; injections 41-80 
1 2 3 4 5 6 7 8 9 10 II (1 
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1Helgl1t 2043•, ·,2051 ;1960 1904 ;1,~2- ''.1714 1734 ·m~ .HWJ; '173.? · .1849 132,11 
Allele 9.3 at THO1 injected ten times with a new block, polymer, buffer, and capillary; Injection 1-16; product 13 days old 
1 2 3 4 5 6 7 8 9 10 II (1 
I Size 186.43 186.43 186.34 186.37 186.28 186.45 186.38 186-42 186.46 186.39 186 Q_Q6 Instrument 1 
l#elgllt ,'.154l . ,1,003 1$7.1. · <1$W ;01,560;J1 t582 1~2 158!ll ':H;ts" t1 :1594 ;1573; 1s:1a 
Allele 9.3 at THO1 injected ten times with new buffer; injections 56-71; product 16 days old 
1 2 3 4 5 6 7 8 9 10 II (1 
I Size 186.36 186.4 186.33 186.43 186.4 186_36 186.38 186.39 186.29 186_4 186 0 04 Instrument 1 
11-l•!ght HSI 1,38 . -~9$ . li,718 1729 1758 · 1&!01 111$2 f!Sti 1 1819 ,;1686 243.57 
Allele 9.3 at THO1 injected ten times with a new capillary after new buffer; injections 77-93 
1 2 3 4 5 6 7 8 9 10 II (1 
I Size 186.29 186_35 186.36 186.34 186_3 186_39 186.39 186.39 186.33 186.34 186 0_04 Instrument 1 I Height 1565 1571) 1600 1638 · 1640 1684 1644 1620; • •1596 . '1658' .. · 1~0 34.35 
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METHOD FOR SIMULTANEOUSLY 
DETERMINING IN A SINGLE MULTIPLEX 
REACTION GENDER OF DONORS AND 
QUANTITIES OF GENOMIC DNA AND 
RATIOS THEREOF, PRESENCE AND EXTENT 
OF DNA DEGRADATION, AND PCR 
INHIBITION WITHIN A HUMAN DNA 
SAMPLE 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of copending U.S. pro-
visional application Ser. No. 60/870,770, filed 19 Dec. 2006, 
the complete contents of which are incorporated herein by 
reference. 
SEQUENCE LISTING 
This application includes as the Sequence Listing the com-
plete contents of the accompanying text file "Sequence.txt", 
created Sep. 18, 2007, containing 2,562 bytes, hereby incor-
porated by reference. 
FIELD OF THE INVENTION 
2 
DNA product measured after each extension step in a PCR 
cycling program (i.e. real-time PCR) (10-13). Real time PCR 
methods incorporate primers that target specific genomic 
sequences in human DNA whose accumulation during 
5 repeated rounds of amplification can be measured and is 
proportional to the amount of input DNA template. Included 
among human loci targeted for real time PCR are Alu 
sequences scattered throughout the genome (8) or sites on the 
X and Y chromosomes (11) whose amplification can provide 
10 data not only on DNA quantity, but also on the sex of the 
sample and the possible existence of male:female mixtures in 
extracts. Information regarding the gender of the person(s) 
contributing the DNA can be of vital importance, especially 
in the investigation of sexual assault cases. For example, if a 
15 forensic sample from a female contains a mixture of both 
male and female DNA, this could support an allegation of 
assault, whereas the absence of male DNA in a sample might 
argue against an assault having occurred. 
Of the methods described above, only those that employ 
20 the use of human specific probes or primers will meet the 
intent of the quality assurance standards in that they will 
produce an estimate of human DNA quantity. However, to 
date, the methods of doing so involve the use of materials and 
instrumentation other than that which is required for PCR 
25 amplification of the DNA. This means that a laboratory that is 
engaged in DNA forensic analysis must either invest in the 
necessary equipment and training, or subcontract the work to 
other labs that are so equipped, both of which options are 
inefficient. 
This disclosure relates to genetic testing in general and, 
more specifically, to determining, in a single polymerase 
chain reaction (PCR) reaction, the quantity, quality, and gen-
der of origin of DNA in a sample, and whether or not the 30 
sample contains PCR amplification inhibitors. 
Another problem that plagues DNA analysts is that some-
times, in spite of a sufficiently high concentration of DNA in 
a sample, amplification of the DNA is inadequate due to the 
presence of PCR inhibitors. Such inhibitors may originate 
from clothing, dirt, etc. to which the sample has been 
BACKGROUND OF THE INVENTION 
It is common practice for forensic laboratories to quantitate 
the amount of human genomic DNA recovered from eviden-
tiary biological samples. Motivation for the quantitation of 
the DNA, which is used as a polymerase chain reaction (PCR) 
template for multiplex amplification of short tandem repeat 
(STR) loci, include minimizing the amplification of partial 
DNA profiles, minimizing allele dropout or imbalance if tem-
plate amounts are too low, or off-scale data, allelic/locus 
imbalance or other spurious artifacts when input template is 
too high (1-4). In addition, the laboratory is required to con-
sume only what is needed to produce a result and retain the 
remaining evidence and/or DNA for independent testing by a 
different laboratory, should the court so order. 
35 exposed. While samples can be "cleaned up" to remove 
inhibitors, valuable sample and time may be wasted in detect-
ing the presence of inhibitors, especially when samples are 
dealt with on a case by case basis. 
The prior art has thus-far filed to provide a convenient 
40 method to, in a single reaction, analyze a DNA sample with 
respect to quantity, quality, presence of inhibitors, and gender 
of donor. In particular the prior art has failed to provide a 
method to obtain this information that requires only the use of 
equipment and personnel trained to carry out routine PCR, 
45 without additional instrumentation, supplies or training. 
Standard 9.3 in the Quality Assurance Standards for Foren-
SUMMARY OF THE INVENTION 
The present invention provides methods for obtaining cru-
cial information about the DNA content of a sample of inter-
est (e.g. a forensic sample) in a rapid, efficient and sensitive 
manner. By utilizing a combination of oligonucleotide prim-
ers as described herein, it is possible to ascertain, in a single 
multiplex PCR reaction, the quantity of human genomic 
sic DNA Testing Laboratories mandates that forensic DNA 
typing laboratories determine the amount of human genomic 50 
DNA recovered from samples (5). Any laboratory desiring 
accreditation/certification by accrediting agencies using 
these or other similar standards must quantitate human DNA 
recovered from biological evidence that is to be used for DNA 
typing. 
Current non-specific methods available for DNA quantita-
tion include the absorbance of ultraviolet light at 260 nm, 
quantitation of fluorescence in genomic DNA co-electro-
phoresed with known amounts of DNA in a "yield gel", and 
quantitation of fluorescence produced by intercalating fluo- 60 
rescent dyes (6). Specific methods for quantitating human 
chromosomal DNA include quantitative hybridization of 
human DNA probes to slot blots or dot blots of dilutions of 
DNA from unknowns and quantitation standards (7), quanti-
tative measurement of fluorescence produced by dyes inter- 65 
calating in Alu sequences amplified from human genomic 
DNA (8,9), and fluorescence produced by accumulating 
55 DNA present in the sample, the gender of the DNA donor ( or 
donors), the "quality" of the DNA (i.e. the extent of DNA 
degradation that has occurred in the sample), and whether or 
not the sample contains significant levels of PCR inhibitors. 
The assay, which is referred to herein as "Q-TAT" for "Quan-
titative template amplification technology", is both sensitive 
and reproducible, and enables a forensic DNA typing lab to 
use existing technology and instrumentation in conjunction 
with a well characterized DNA standard to produce concen-
tration estimates of DNA in biological samples. Q-TAT thus 
represents an alternate method useful for the quantitation of 
human genomic DNA prior to amplification of STR loci used 
for identity testing purposes. In addition, the actual cost of 
US 8,153,372 B2 
3 
carrying out other similar methods is about $10.00, even 
though the charge to the consumer is about $40.00. In con-
trast, the cost of carrying out a Q-TAT reaction can be less 
than $1.00, so even with a commercial markup, the cost to the 
consumer will be significantly less than that of currently 5 
available methods. 
4 
b) a second primer set comprising synthetic oligonucle-
otide primers directed against a human Y-chromosome spe-
cific gene or a human X-chromosome specific gene, or both; 
c) a third primer set comprising synthetic oligonucleotide 
primers directed against a non-human reporter genetic 
sequence; and 
d) a reporter gene. In general, amplicons produced by PCR 
amplification of the human Y-chromosome specific gene and 
the human X-chromosome specific gene are shorter than 
The method, involves carrying out a single, PCR multiplex 
reaction utilizing primer sets specific for amplifying the 
human amelogenin locus, an X- and/or Y-chromosome spe-
cific gene that is shorter on the X chromosome, an additional 10 amplicons produced by PCR amplification of the human 
amelogenin locus. In one embodiment of the invention, the 
Y-chromosome specific gene is Sex-Determining RegionY 
(SRY). In another embodiment of the invention, the non-
human reporter sequence is a luciferase gene. The synthetic 
Y chromosome specific marker known as SRY, and a heter-
ologous, non-human reporter gene. DNA quantitation is 
accomplished by comparing the fluorescence of amplicons 
produced from the X and/or Y amelogenin locus or the SRY 
locus with fluorescence in a standard curve of fluorescence 
from amplicons obtained from known quantities of reference 
DNA. The gender of the DNA donor( s) can be determined by 
comparing the relative fluorescence ofX and Y amplicons of 
amelogenin. The X chromosome version of amelogenin is 
shorter than the Y chromosome version, and the two can thus 20 
be readily distinguished from each other. The extent of deg-
radation in the sample is determined by comparing the 
amount of fluorescence of amplicons of amelogenin with 
fluorescence from amplicons from a shorter X- and/or Y-chro-
mosome specific gene, such as the Sex-Determining Region Y 25 
(SRY) gene. Use of an additional Y-chromosome specific 
gene also serves as a "back-up" indicator of the gender male 
DNA donors, if the male DNA donor has a mutation that 
prevents amelogenin amplification with primers specific for 
the predominant form of the gene. Finally, the presence of 30 
PCR inhibitors in the sample can be ascertained by compar-
ing the fluorescence levels of amplicons of a non-human 
reporter DNA sequence that is added to and co-amplified with 
the sample, with fluorescence in a control reaction containing 
15 oligonucleotide typically includes a detectable label, e.g. a 
fluorescent label. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is graph of standard curves produced using male 
reference DNA and Q-TAT in 10 independent assays. 
FIGS. 2A-B. A, graph of a comparison of Quantiblot® and 
Q-TAT quantitation methods with shared human DNA 
samples. B, graph of estimates of DNA quantity in the posi-
tive control sample in Profiler Plus and Identifiler STR typing 
kits. 
FIG. 3 is a graphical comparison of real time PCR and 
Q-TAT quantitation methods with shared human DNA 
samples. 
a known quantity of the reporter sequence and that is inhibi- 35 
tor-free. 
FIGS. 4A-B. Imperfect Standard Curve A, This standard 
curve was produced using the NIST SRM 2372 Standard A 
male sample assayed by the improved multiplex assay from 
three independent analyses. Standard curves were produced 
by amplifying a serial dilution of the Standard A male sample 
as described in Materials and Methods. At each data point, the 
fluorescence incorporated into the SRY amplicon from three 
The method involves the steps of obtaining a sample; cre-
ating a reaction mix by combining an aliquot of the sample 
and DNA encoding a non-human reporter sequence; and PCR 
amplifying the reaction mix in a single multiplex PCR reac-
tion using a plurality of primer sets. The primer sets include a) 
a first primer set comprising synthetic oligonucleotide prim-
ers directed against a human amelogenin gene; b) a second 
primer set comprising synthetic oligonucleotide primers 
directed against a human Y-chromosome specific gene or a 
human X-chromosome specific gene, or both; and c) a third 
primer set comprising synthetic oligonucleotide primers 
directed against said non-human reporter sequence. Finally, 
the method involves the step of detecting PCR amplicons 
produced in said step of PCR amplifying. Results obtained in 
said detecting step are indicative of the genomic DNA quan-
tity, the extent of genomic DNA degradation, the gender of 
the genomic DNA donor(s), and the presence of PCR inhibi-
tors in the sample. In general, amplicons produced by PCR 
amplification of the human Y-chromosome specific gene and 
the human X-chromosome specific gene are shorter than 
amplicons produced by PCR amplification of the human 
amelogenin locus. In one embodiment of the invention, the 
Y-chromosome specific gene is Sex-Determining RegionY 
(SRY). In another embodiment of the invention, the non-
human reporter sequence is a luciferase gene, e.g. Sea pansy 
luciferase. The synthetic oligonucleotides typically include a 
detectable label, e.g. a fluorescent label. 
A kit for carrying out the method is also provided. Such a 
kit typically comprises: 
a) a first primer set comprising synthetic oligonucleotide 
primers directed against a human amelogenin locus; 
separate assays and the mean of the three assays is shown 
along with error bars reflecting a coefficient of variation of 
15.55% at all concentrations ofinput reference DNA.A linear 
40 regression line of the data from the average of the three 
separate assays (R2=0.784) is also shown. Each data point 
was gathered by an ABI Prizm 310 Genetic Analyzer using 
GeneScan® Analysis version 3.1.2 with the default settings 
for peak analysis. We noted no difference in the estimation of 
45 peak height by changing the default peak analysis settings to 
"light" or "no" smoothing or by switching between the vari-
ous size-calling settings. Changing these settings does, how-
ever, effect the estimation of peak area by causing broad, 
truncated peaks to have a lower RFU value because they are 
50 smoothed. B, This standard curve was produced using the 
NIST SRM 2372 Standard B male sample assayed by the 
improved multiplex assay from three independent analyses. 
Standard curves were produced by amplifying a serial dilu-
tion of the Standard B female sample as described in Mate-
55 rials and Methods. At each data point, the fluorescence incor-
porated into the X amplicon from three separate assays and 
the mean of the three assays is shown along with error bars 
reflecting a coefficient of variation of 22.13% at all concen-
trations of input reference DNA. A linear regression line of 
60 the data from the average of the three separate assays 
(R2 =0.9288) is also shown. Each data point was gathered by 
an ABI Prizm 310 Genetic Analyzer using GeneScan® 
Analysis version 3.1.2 with the default settings for peak 
65 
analysis. 
FIGS. SA-B. Perfect Standard Curve A, This standard 
curve was produced using the NIST SRM 2372 Standard A 
male sample assayed by the improved multiplex assay from 
US 8,153,372 B2 
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three independent analyses. Standard curves were produced 
by using the same samples of Standard A male described in 
the FIG. 4a legend, but the range was collapsed to the data 
points from the 63 pg/µL, 125 pg/µL, 250 pg/µL, and the 500 
pg/µL dilutions only. At each data point, the fluorescence 5 
incorporated into the SRY amplicon from three separate 
assays and the mean of the three assays is shown along with 
error bars reflecting a coefficient of variation of 12.98% at all 
concentrations of input reference DNA. A linear regression 
line of the data from the average of the three separate assays 10 
(R2=0.9984) is also shown. B, This standard curve was pro-
duced using the NIST SRM 2372 Standard B female sample 
assayed by the improved multiplex assay from three indepen-
dent analyses. Standard curves were produced by using the 
same samples of Standard B female described in the FIG. 4b 15 
legend, but the range was collapsed to the data points from the 
63 pg/µL, 125 pg/µL, 250 pg/µL, and the 500 pg/µL dilutions 
only. At each data point, the fluorescence incorporated into 
the X amplicon from three separate assays and the mean of the 
three assays is shown along with error bars reflecting a coef- 20 
ficient of variation of 25 .66% at all concentrations of input 
reference DNA. A linear regression line of the data from the 
average of the three separate assays (R 2 =0.998) is also shown. 
FIGS. 6A-C. Accuracy of the Improved Multiplex Assay. 
A, Standard curves were produced by using the same dilu- 25 
tions of the NIST Standard A male as described in the FIG. Sb 
legend. At each data point, the total human DNA content of 
the four NIST StandardAdilutions (63 pg/µL, 125 pg/µL, 250 
pg/µL, and 500 pg/µL) were compared to the standard curve 
presented in FIG. Sb by summing the fluorescence of the 30 
Amelogenin X andAmelogenin Y amplicons from three sepa-
rate assays. The mean estimated concentration of the three 
assays is shown along with error bars reflecting a coefficient 
of variation of21.55% at all concentrations ofinput reference 
DNA. A linear regression line of the data from the average of 35 
the three separate assays (R2=0.9992) is also shown. B, Stan-
dard curves were produced by using the same dilutions of the 
NIST Standard B female as described in the FIG. Sb legend. 
At each data point, the total human DNA content of the four 
NIST Standard B dilutions ( 63 pg/µL, 125 pg/µL, 250 pg/µL, 40 
and 500 pg/µL) were compared to the standard curve pre-
sented in FIG. Sb by summing the fluorescence oftheAmelo-
genin X andAmelogenin Y ( absent in this sample) amplicons 
from three separate assays. The mean of the three assays is 
shown along with error bars reflecting a coefficient ofvaria- 45 
tion of 13.95% at all concentrations of input reference DNA. 
A linear regression line of the data from the average of the 
three separate assays (R2 =0.9985) is also shown. C, Standard 
curves were produced by using the same dilutions of the NIST 
Standard A male as described in the FIG. Sa legend. At each 50 
data point, the total human DNA content of the four NIST 
Standard A dilutions (63 pg/µL, 125 pg/µL, 250 pg/µL, and 
500 pg/µL) were compared to the standard curve presented in 
FIG. Sa by the fluorescence of the SRY amplicon from three 
separate assays. The mean of the three assays is shown along 55 
with error bars reflecting a coefficient of variation of26.05% 
at all concentrations of input reference DNA. A linear regres-
sion line of the data from the average of the three separate 
assays (R2 =0.9979) is also shown. 
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five-second standard curve; B, the four-second standard 
curve; C, the three-second standard curve; D, the two-second 
standard curve; E, the one-second standard curve. For each 
standard curve, the slope of the line of regression, they-in-
tercept of the line ofregression, and the R2 value of the data 
were calculated. The dilutions that had truncated peaks do not 
have a value in the table. The LOQ (MIT) is the "limit of 
quantification" for the CEFD device sometimes referred to as 
the "match interpretation threshold" by DNA analysts. 
FIG. 8. Example Electropherogram of the four amplicons 
produced by the improved multiplex assay in the NIST SRM 
2372 Standard A male, the NIST SRM 2373 Standard B 
female, and a blank sample. A Genotyper® 2.5.2 macro was 
built that would correctly call and label each amplicon in the 
improved multiplex assay. The data shown from top to bottom 
is a blank sample consisting of sterile deionized H20, the 
NIST SRM 2372 Standard Bat a concentration of250 pg/µL, 
and the NIST SRM 2372 Standard A at a concentration of250 
pg/µL. 
FIG. 9. Specificity of the Improved Multiplex Assay on a 
panel of primate blood samples 
Five non-human primate blood samples were quantified 
using the improved multiplex assay. The Amelogenin X 
amplicon was produced in all primate samples. The single 
male non-human primate sample did not exhibit production 
of the Amelogenin Y or the SRY amplicons. 
FIG. lOA-B. The Effect of EDTA Concentration on the 
ImprovedMultiplexAssay. A, the amplicon peak-height RFU 
intensities for each of the four amplicons of the improved 
multiplex assay post-amplification with increasing mM 
amounts ofEDTA were graphed; B, the ratio of peak-height 
RFU intensities of all four amplicons to the peak-height 
intensity of the pRL amplicon was graphed with increasing 
mM amounts of EDTA. The pRL ratio to itself is, thereby, a 
constant 1.0. The ratio of Amelogenin Y intensity to pRL 
intensity is less than one between 0.5 and 0.8 mM EDTA 
concentration, but after 0.8 mM EDTA concentration, all 
amplicons are of greater intensity then pRL, indicating that 
pRL is the first amplicon to completely "drop out" when a 
chemical inhibitor is present in a DNA sample. 
FIG. llA-B. Sensitivity to detect Male-only DNA in a 
Preponderance of Female DNA. A, the RFU peak-height 
intensities of the Amelogenin Y and SRY amplicons were 
observed in DNA to DNA samples in which the male DNA 
concentration stayed at a constant 125 pg/µL and the female 
DNA concentration increased. The Amelogenin Y amplicon 
"drops out" after a 1 in 10 ratio of male to female DNA. The 
SRY amplicon does not appear to drop out even when 400 
times more female DNA is present in the sample. B, the RFU 
peak-height intensities oftheAmelogenin Y and SRY ampli-
cons were observed in whole male blood to whole female 
blood ratios as indicated and then dried onto FTA paper. A 
single hole punch (1.5 mm in radius) of the dried mixture was 
then DNA extracted and analyzed with the improved multi-
plex assay. The male blood concentration was not constant in 
these ratios. The Amelogenin Y amplicon "drops out" after a 
1 in 20 ratio of male to female DNA. The SRY amplicon 
"drops out" when 100 times more female blood was mixed 
with the male blood. 
FIG. 12A-B. The Effect of a DNA Degradation Time-
course upon the Four Amplification Products of the Improved 
Multiplex Assay. A, the amplicon peak-height RFU intensi-
ties were graphed for each of the four amplicons of the 
improved multiplex were gathered post-amplification from a 
FIGS. 7A-E. Standard curve results gathered by a "sensi- 60 
tive" CEFD and the effect of decreasing electrokinetic injec-
tion time. A dilution series of NIST SRM 2372 Standard B 
was made as described in the Materials and Methods. The 
dilution series was injected for five seconds, four seconds, 
three seconds, two seconds, and one second on the sensitive 
ABI Prizm 310 Genetic Analyzer. A standard curve was gen-
erated from the data gathered for each injection time. A, the 
65 DNase I digestion of a pure male DNA sample subjected to 
increasing time periods of digestion. B, the ratio of the peak-
height RFU intensity of the SRY amplicon at each time-
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period of digestion to the peak-height intensity of the sum of 
theAmelogeninX andAmelogenin Y amplicons at each time 
period of digestion was graphed. The time zero ratio is 
between 1 and 1.5. The ratio of these amplicons rises to above 
3 .0 between the one and five-minute time periods of digestion 5 
and between the five and thirty-minute time periods of diges-
tion. At these time periods the improved multiplex assay is 
showing that the pure male sample DNA fragments are less 
than 200 basepairs in length but more than 100 base-pairs in 
length. 
FIG. 13. Graphic Representation of Estimated Concentra- 10 
tion of DNA from Any Quantification Method that Exhibits a 
Percent CV of ±30% versus the Actual Amount oflnput DNA 
Targeted for the Identifiler™ or Yfiler™ DNA Testing Reac-
tions. This is a graphic representation of any DNA quantifi-
cation method with a CV of30% to target 1000 pg in 10 µl for 15 
profiling with any DNA kit requiring the input of 1000 pg 
DNA in 10 µl when the DNA testing kit has a successful range 
of input DNA of between 500 pg to 1500 pg. 
FIG. 14. Reproducibility of Estimation of DNA Content of 
Unknown Samples by the Repetitive Analysis of Pure Male 20 
and Pure Female Unknowns. A pure female mock evidence 
sample and a pure male mock evidence sample was diluted by 
halves as described in Materials and Methods. Each dilution 
was amplified multiple times and injected for five seconds on 
a 310 genetic analyzer. The height RFU for the amelogenin 25 
and SRY amplicon from each amplification was averaged and 
the standard deviation and coefficient of variation was calcu-
lated. The height RFU values were compared to a standard 
curve and the estimation of total human and total male DNA 
was determined for each sample. The average, standard 30 
deviation and coefficient of variation for each estimated 
amount of DNA was calculated. The standard deviation and 
coefficient of variation for both the height RFU and estimated 
amount of DNA for each dilution was calculated as well as the 
average standard deviation and coefficient of variation in the 35 
male sample from the averages of the male-only and total 
human from the male sample. 
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ti gator to determine, in a single PCR reaction: 1) the amount 
of total human DNA present in the sample; 2) the quality (i.e. 
extent of degradation) of the DNA 3) whether the sample 
contains DNA from a male donor, a female donor, or both; 
and 4) whether or not PCR inhibitors are present in the 
sample. 
The ability to determine the quantity of DNA allows the 
investigator to design appropriate conditions for carrying out 
PCR reactions to identify the donor without using either too 
little DNA (and thus risking an insufficient signal for analy-
sis) or too much DNA (and thus wasting the sample and 
interfering with the signal that is to be analyzed). Thus, the 
method allows an investigator to choose among several 
samples to send for further DNA profiling, orto select the best 
conditions for profiling, or to further prepare samples for 
profiling, i.e. to send the best possible sample, a sample that is 
likely to produce reliable, useful results when further DNA 
typing is carried out. 
Forensic samples are sometimes recovered from a scene in 
which the degradation of the DNA template is accelerated. 
For example, numerous DNA samples from the World Trade 
Center disaster were badly degraded due to the heat of the fire. 
The ability to determine the quality (i.e. to provide an esti-
mate of the integrity and/or degradation) of DNA in a sample 
is accomplished through the inclusion of primers in the reac-
tion that direct the amplification of two differently sized 
templates. If the DNA is degraded, the smaller template 
would be expected to be less affected than the larger template, 
and thus the quantity of amplicons produced from the smaller 
product would be greater than the amount produced from the 
larger template. This analysis allow an investigator to more 
accurately predict the successful amplification oflonger alle-
les suitable for DNA profiling of the sample, and to adjust 
PCR reaction conditions accordingly. 
The ability to determine the gender of the DNA donor can 
be extremely helpful. For example, is sexual assault cases, a 
sample taken from a female would logically contain both 
female and male DNA if an assault has actually occurred. 
Absence of male DNA in a sample may indicate that there 
40 was, in fact, no assault. In other words, Q-TAT provides the 
forensic community with the ability to terminate analysis of 
non-probative evidentiary samples (i.e. no male DNA 
present) before expending resources for unnecessary DNA 
FIG. 15. Size-Calling Precision and Peak-Height Quanti-
fication Precision in Five 310 CEFD devices. To determine 
the percent CV for a CEFD device, we serially injected ( eigh-
teen times in a row) one sample of the amplification products 
from an AmpFlSTR® Identifiler™ DNA profiling reaction 
performed on the Identifiler™ female positive control 994 7 A 
sample provided with the Identifiler™ kit on five different 
CEFD devices. By analyzing the average peak-height fluo- 45 
rescence data and size-calling data ofonly the THO! 9 .3 allele 
peak, we determined the percent CV of a CEFD device for 
size-calling and for electrokinetic injection and fluorescence 
detection of a sample by averaging this data and calculating 
percent CV over the eighteen serial injections of this single 
sample. Because a single sample was analyzed over eighteen 
injections, no pipetting error would be included in the CV 
value determined. The lower five segments of this table 
describe the data gathered over ten serial injections of a 
sample exhibiting the THO! 9.3 allele for just the first CEFD 55 
device from the top segment of the table. The conditions of the 
CEEFD device during the collection of the data for each 
grouping of ten serial injections is described above each 
segment. We concluded that with proper attention to CEFD 
maintenance issues that effect quantification precision, any 60 
CEFD device can have a percent CV of 5% or less. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The Q-TAT assay is a PCR based assay that provides useful 
information about a DNA sample. The assay permits an inves-
profiling. 
Finally, DNA recovered from certain types of forensic 
substrates (blue jeans, blood, or soil for example) often con-
tains chemicals that will inhibit the PCR reaction. Thus, the 
Q-TAT assay includes a non-human control DNA template 
whose amplification is expected unless a forensic DNA 
50 sample contains inhibitors. The ability to detect the presence/ 
absence of PCR inhibitors is a boon in that an investigator will 
then know whether or not extra clean-up steps should be 
carried out to rescue the DNA in a sample to make it useful for 
DNA typing, thereby avoiding needless waste of samples and 
resources. 
A particular advantage of the invention is that the Q-TAT 
assay is carried out in a single PCR reaction and requires the 
same equipment, supplies and personnel training that already 
exist in facilities that conduct DNA testing (e.g. DNA profil-
ing or typing) using PCR technology. No stand alone proce-
dures are required. In other words, the assay utilizes PCR and 
electrophoresis with fluorescent detection/quantitation as 
used in typical DNA profiling, precluding the need for new 
instrumentation, methodology, or quality assurance associ-
65 ated with slot-blot or real-time PCR. To perform the Q-TAT 
assay, a commercially available human sex typing kit, a ther-
mal cycler, and a genetic analyzer are all that are required 
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Q-TAT thus bridges the information gap between biologi-
cal screening and final DNA profiling. Further, while the 
assay is suitable for use on a sample by sample basis, it may 
be advantageously used to screen large numbers of samples 
prior to subjecting them to a detailed PCR analysis. This is 
especially helpful given the large number of samples that are 
currently backlogged at DNA analysis facilities. For 
example, the assay may be used to initially screen several 
hundred or several thousand samples to obtain the informa-
tion described above. The samples can then be divided into 
categories such as those which must be further processed to 
remove PCR inhibitors prior to final PCR analysis, and those 
which do not need further processing. In addition, for cases 
where such knowledge is pivotal, samples that are putative 
sexual assault evidence and that contain male DNA even 
though obtained from a female could be classified as suitable 
for further analysis, whereas if no male DNA is detected, they 
could be eliminated. Finally, because the quantity and quality 
10 
labels, affinity labels, electromagnetic labels, etc. In one 
embodiment of the invention, the label is a fluorescent dye, 
examples of which include but are not limited to FAM (a 
derivative offluorescein), Oregon Green®468, BODIPY FL, 
5 JOE, TAMRA, ROX, Texas Red, VIC, NED, the CY (cya-
nine) dyes, LIZ, etc. In a preferred embodiment, the label is 
the fluorescent dye FAM. 
The Q-TAT PCR reaction mixture contains a suitable quan-
tity of a non-human gene. In one embodiment of the inven-
10 tion, the non-human gene is a luciferase gene, e.g. luciferase 
from the Sea pansy, an ocean coelenterate. The probability 
that a biological sample from a mammal ( e.g. human) would 
contain such DNA is vanishingly small. However, those of 
skill in the art will recognize that other non-human genes that 
15 are readily amplified and quantitated may also be used in the 
practice of the invention. In a preferred embodiment of the 
invention, the Q-TAT reaction mix contains about 0.5 to about 
1.0 pg of a recombinant plasmid containing the Sea Pansy 
of the DNA in a sample has been determined by Q-TAT, PCR 
reaction conditions for samples deemed immediately suitable 20 
for further processing could be adjusted to maximize reliable 
signals in further PCR analysis, without wasting valuable 
sample. 
luciferase gene. 
Each PCR reaction contains an aliquot of extract from a 
sample to be analyzed, plus a known quantity of non-human 
DNA and a DNA polymerase. Those of skill in the art will 
recognize that several DNA polymerases are commercially 
available and could be used in the practice of the invention, The Q-TAT assay is a multiplex PCR reaction in which, in 
one embodiment, primers directed against the human amelo-
genin locus, the Sex-Determining Region Y (SRY) gene, and 
a non-human gene are included in a PCR reaction mix. The 
amelogenin locus is present in both the X and Y chromo-
somes, but the locus is longer in the Y chromosome. There-
fore, amplification of amelogenin produces products of dif-
ferent size, depending on whether the locus on of the X or Y 
chromosome is amplified. Amplification of samples contain-
ing male or a mixture of male and female DNA will produce 
both products. Amelogenin thus serves as an indicator of the 
gender of the DNA donor(s). Further, comparison of the 
quantity of fluorescence produced by Q-TAT amplification of 
amelogenin to fluorescence produced by a known quantity of 
the locus indicates the concentration of DNA in the sample. 
The SRY gene is located only on the Y chromosome. Ampli-
fication of this gene confirms that male DNA is present in the 
sample and, because it is shorter than either the X or Y 
amelogenin locus, serves as an indicator of the quality of 
DNA in a sample that contains male DNA. Moreover, since 
amelogenin X and Y amplicons exhibit sizes of 210 bp and 
216 bp respectively, integrity as well as concentration of the 
genomic DNA template can be assessed. The inclusion of a 
non-human gene of known quantity in the Q-TAT reaction 
mix allows an assessment of the presence/absence of PCR 
inhibitors. If no inhibitors are present, the gene will be ampli-
fied optimally and produce a predictable signal. If the 
expected signal is diminished, then PCR inhibitors are likely 
present. If no male DNA is present in the sample, the amount 
of female DNA can be quantitated and the presence of inhibi-
tors can be detected as described, without estimating the 
extent of degradation. 
In another embodiment of the invention, a human X-chro-
mosome specific gene is amplified. Examples ofX-chromo-
some specific genes include but are not limited to hypoxan-
thine-guanine phosphoribosyl transferase (HGPRT), 
coagulation factor VIII, etc. In yet another embodiment of the 
invention, primers for both a Y-chromosome specific gene 
and an X-chromosome specific gene are included in the reac-
tion mixture. 
To carry out the Q-TAT reaction, one member of each 
primer set is labeled. Many types oflabels that are suitable for 
use in PCR reactions are known to those of skill in the art, 
including but not limited to fluorescent labels, radioactive 
25 examples of which include but are not limited to Thermus 
aquaticus ("Taq") polymerases such as AmpliTaq® and 
AmpliTaq Gold®, commercially available blends of Taq 
DNA polymerase and proofreading enzymes, Pyrococcus 
furiosus ("Pfu") polymerases such as Pfu-X polymerase and/ 
30 or commercially available genetically engineered Pfu-X 
polymerase; polymerases from species such as Thermas fla-
vus, Thermus themophilius, Thermus litoris, Thermaotoga 
maritima, etc. In preferred embodiments, the DNA poly-
merase is AmpliTaq Gold® (Applied Biosystems, Inc.) or a 
35 preblended master mix containing Taq polymerase such as 
Go-Taq® from Promega Corp. (Madison, Wis.). Amplifica-
tion is carried out during a thermal cycling program designed 
not to exhaust reactants. Those of skill in the art are well 
acquainted with the development of PCR cycling programs, 
40 which are described, for example, in Butler J M (2005). 
Forensic DNA Typing. Biology, Technology and Genetics of 
STR Markers. Burlington, Mass.: Elsevier Academic Press. 
Following completion of the cycling, aliquots of PCR prod-
ucts (amplicons) are separated and the associated signals are 
45 quantitated by any of several suitable methods known in the 
art. For example, amplicons may be separated by capillary 
electrophoresis ( e.g. in anABI 310 Prism GeneticAnalyzeror 
other multi-capillary genetic analyzer platform). Signals 
associated with the non-human gene, SRY, and X +/-Y ampli-
50 cons are captured and can be quantitated, for example, using 
standard curves amplified from known quantities of reference 
DNA (e.g. as relative fluorescent units (rfus) when fluores-
cent labels are used). The relative signal inX andY amplicons 
can be compared with the signal in amplicons produced in 
55 reactions carried out with known amounts of human DNA 
and the gender(s) of origin of the sample can be determined. 
The presence of inhibitors is determined by the signal present 
in the amplicon produced from the non-human gene target 
present in a constant amount in each sample. Reduction or 
60 obliteration of the non-human signal in the unknown sample, 
compared to the signal in a control reaction known to contain 
no PCR inhibitors, would indicate the presence of inhibitors 
in the DNA sample, and the need for cleanup of the sample. 
Finally, ifamelogenin-Y or SRY amplicons are detected, then 
65 the presence of male DNA in the sample is confirmed. In 
addition, the SRY amplicon is about one-half the size of the 
amelogenin products. Therefore, if the ratio of the amount of 
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SRY amplicon signal to amelogenin amplicon signal is 
greater than 1, it would suggest degradation of the DNA 
template, suggesting the use of a DNA typing methodology 
that favors producing results from degraded templates. 
Those of skill in the art will understand that experienced 5 
practitioners are frequently able to predict a reasonable range 
oflikely DNA concentrations within an unknown sample, and 
may thus be able to select a suitable quantity of the unknown 
sample for analysis. However, in many instances it may be 
preferable to test several dilutions of the sample ( e.g. from 10 
about 2 to about 5 or with the intention of "bracketing" 
optimal conditions for PCR amplification and signal capture. 
For example, testing a single 25 fold dilution along with an 
undiluted sample would extend the useful dynamic range of 
the Q-TAT assay from about 50 pg/µ! up to over 10 ng/µl, a 15 
rnage useful for most crime scene samples consisting of bio-
logical evidence. The additional data points that are obtained 
can be helpful to confirm the quantity/concentration or DNA 
12 
alcohol (9:0.96:0.04 vol/vol) extraction (14). Reference 
samples were extracted using the same methods, or, using 
inorganic extraction methods based on the original work of 
Miller et. al. (15). The male and female DNA used to produce 
the standard curves were extracted from blood samples sup-
plied by lab workers and were dispensed in aliquots in 10 mM 
Tris-Cl pH 8.3+0.1 mM EDTA (TE-4) and stored at -20° C. 
for repetitive use. Quantities of DNA in these reference stan-
dards were established by absorbance at 260 nm as well as 
through the use of a yield gel, comparing ethidium bromide 
fluorescence produced by a range of known concentrations of 
lambda DNA co-electrophoresed with dilutions of the human 
genomic DNA samples to be used as quantitation standards. 
Concentration estimates of the human standards were further 
evaluated by amplifying what was calculated to be a 1 ng 
aliquot of reference DNA (based upon theA260 and yield gel 
estimates) with the Profiler Plus STR typing kit (Applied 
Biosystems, Foster City, Calif.) according to recommenda-
tions from the supplier. Peak relative fluorescence unit (rfu) in the unknown, experimental sample, as well as to confirm 
the results obtained with the other amplified loci. 20 measurements of alleles amplified from the reference tem-
plate exhibited average peak heights of 1000-3000 rfu, which 
is consistent with expectations when using 1 ng of good 
quality DNA template. 
In a comparison study incorporating shared samples (see 
Examples below), Q-TATwas found to be more sensitive than 
widely used slot-blot methods but somewhat less sensitive 
than real time PCR. Nevertheless, incorporating the Q-TAT 
method into the normal workflow may be more attractive to 25 
some laboratories than making the commitment to add real 
time PCR technology, which will involve funding, space allo-
cation, training, and other QA/QC issues. Among samples 
containing DNA concentrations ranging from 100 pg/ul to 
2-4 ng/ul, Q-TAT produced DNA concentration estimates that 30 
agreed well with either Quantiblot® or real time PCR. Q-TAT 
was reproducible with a typical coincidence of variation of 
about 35%. Quantitation of human DNA in the studies 
involved summing fluorescence in amelogenin X and Y 
amplicons in unknowns and quantitation standards. However, 
analyzing fluorescence in X and Y amplicons individually 35 
could also allow estimates of male and female DNA present in 
mixtures to be made. The Q-TAT method will detect as little 
as 20-30 pg of human DNA and has a dynamic range that 
extends to about 500 pg. 
Those of skill in the art will recognize that the methods of 40 
the invention can be applied to the analysis of DNA from 
many sources and for many reasons, examples of which 
include but are not limited to: analysis of forensic samples, 
especially samples associated with sexual assault cases, but 
also for identification of unidentified persons ( either living or 45 
dead); paternity testing; genetic testing for genealogical pur-
poses; genetic testing of any type of remains, e.g. fossilized, 
mummified, etc.; molecular testing for human genetic dis-
eases, etc. 
Samples that may be assayed by the methods include any 50 
that contain or are believed to contain DNA, such as swabs 
(e.g. vaginal, buccal, etc.); hair; blood; skin or skin cells; 
blood; prenatal samples ( e.g. amniotic fluid); tissue biopsies, 
etc. 
In a preferred embodiment, the assay is conducted on 
samples obtained from mammals such as humans. However, 55 
those of skill in the art will recognize that the methods may 
readily be adapted to analyze DNA samples from other mam-
mals or other species as well. 
PCR Amplification and Genetic Analysis 
Samples were amplified by PCR using either a PTC-200 
(MJ Research, Reno, Nev.) or an ABI 9700 thermal cycler 
(Applied Biosystems, Foster City, Calif.). Profiler Plus 
amplifications were set up following the instructions supplied 
with the STR typing kit (Applied Biosystems, Fullerton, 
Calif.). 
Amplification ofX and Y products using the amelogenin, 
sex typing kit (Promega Corp., Madison, Wis.) was per-
formed as directed by the kit instructions except Ampli-Taq 
Gold DNA polymerase (Applied Biosystems, Foster City, 
Calif.) and GoldSTR reaction buffer (Promega Corp., Madi-
son, Wis.) were substituted in place of the reagents recom-
mended or supplied with the kit. In addition, 12.5 µI reaction 
volumes were substituted for the 25 µI volumes specified in 
the manufacturer's protocol. The primers in this kit are 
labeled with fluorescein and are reasonably specific for pri-
mate DNA although small amounts of product whose size 
differs from the human products can be produced with the 
genomic DNA from other species as well (16). 
Amplification products produced either with the Ameloge-
nin or Profiler Plus kits were mixed with formamide (Applied 
Biosystems, Foster City, Calif.) containing GS350 or GS500 
size standards (Applied Biosystems, Foster City, Calif.) 
according to recommendations of the supplier. The samples 
were then subjected to electrophoresis and fluorescent analy-
sis with the aid ofanABI Prism 310 Genetic Analyzer (Ap-
plied Biosystems, Foster City, Calif.). 
Each Q-TAT assay incorporated the creation of a standard 
curve produced by quantitating fluorescence in X or X + Y 
amplicons produced with 0, 31.25 pg, 62.5 pg, 125 pg, 250 
pg, or 500 pg of human reference DNA template. The stan-
dard curve was produced as follows: DNA serving as the 
human quantitation standard was diluted to 500 pg/µ! in 
dH20 initially and then serially diluted 2 fold to establish the 
concentration range. One microliter aliquots of each dilution 
EXAMPLE 1 
Materials and Methods 
60 were then used as template for amplification ofX, or X and Y 
alleles in a 12.5 µI PCR reaction. Each assay also included a 
100 pg aliquot of positive control DNA contained within the 
Profiler Plus STR typing kit (Applied Biosystems, Foster 
DNA Extraction 
DNA was extracted from non-probative forensic samples 65 
used in this study with standard methods employing SDS and 
proteinase K digestion followed by phenol:CHCl3 :isoamyl 
City, Calif.) to serve as an internal quantitation control. 
Data Analysis 
For estimation of the DNA concentrations in unknowns, 
the relative fluorescence in the X ( and possibly Y) amp Ii cons 
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were compared with the fluorescence in X + Y amplified from 
known amounts of reference DNA template using the follow-
ing strategy: The area under the curves of the X/Y products in 
each dilution of reference DNA was summed and normalized 
for the different injections through comparison to the total rfu 5 
contained within the 200 bp standard present in the GS350 or 
GS500 size standards. Since the size standard mixture is 
present in constant amounts in each sample ( due to the use of 
14 
Several features of the Q-TAT method are apparent from 
FIG. 1. The sensitivity of the method for reliably detecting 
human DNA is operationally about 20-30 picograms. This 
level of sensitivity should be adequate for most forensic appli-
cations. It is also apparent from FIG. 1 that one limitation of 
the assay is the dynamic range which extends only over a 
10-20 fold span of concentration before the curve begins to 
plateau, possibly due to depletion of primers or other reac-
tants in the amplification reaction, or for as yet undefined a master mix of formamide/size standard that is prepared and 
aliquoted into the sample tubes needed for each assay), varia-
tion in the fluorescence in XN amplicons resulting from 
subtle injection fluctuations or laser/CCD camera variability 
can be normalized across the run. Normalized fluorescence in 
X/Y amplicons per input ng of reference DNA could then be 
computed from the slope of the standard curve. Fluorescence 
in XN products from unknowns was simply plotted on the 
standard curve to estimate their respective template concen-
trations. 
10 reasons as discussed by Morrison and Gannon (17). Reducing 
the number of cycles could help alleviate this problem, but 
sensitivity could be compromised as a consequence. As an 
alternative approach, a small dilution series of an extract 
would likely produce a result within the acceptable range of 
15 the standard curve. The PCR conditions chosen therefore 
DNA Quantitation Using Quantiblot and Real Time PCR 
Estimates of DNA concentration in samples processed by 20 
the Tulsa Police Laboratory were produced using blotting/ 
hybridization methods incorporated into the Quantiblot kit 
available from Applied Biosystems (Foster City, Calif.). 
Quantiblot estimates were made following colorimetric visu-
alization of probe hybridization to quantitation standards and 25 
unknowns slot-blotted onto nylon membrane according to 
manufacturer's instructions. The highest concentration of 
quantitation standard on the slot blot contained 8 ng/µl (the 
QA++ standard) of human genomic DNA supplied with the 
QB kit. Serial two-fold dilutions were made of this DNA 30 
sample and blotted on the membrane with the least concen-
trated sample corresponding to 0.0325 ng/µl (the QG 
sample). In estimating the DNA concentration in unknowns 
however, any sample producing a color fainter than the 0.125 
ng/µl standard (the QE standard) was labeled as <QE and no 35 
attempt were made by the analyst to estimate concentration 
more accurately. 
represent a good working balance between sensitivity and 
usable concentration range for input DNA. 
FIG. 2A is a graph of a comparison of Quantiblot® and 
Q-TAT quantitation methods with shared human DNA 
samples. A group of 30 non-probative human DNA samples 
extracted from suspects, victims, and evidentiary item were 
quantitated with both QB and Q-TAT. Estimates of DNA 
concentration produced for each sample with the two meth-
ods were then plotted as a scatter plot. DNA concentration 
estimates were made using QB by an analyst with several 
years experience using the method and consisted of assigning 
unknowns to concentration categories spanning a range from 
QA++ (8.0 ng/ul)to <QE (<0.125 ng/ul). The analyst does not 
incorporate the QF (0.06 ng/ul) and QG (0.03 ng/ul) catego-
ries suggested in the instructions provided with the QB kit 
into concentration estimates of unknowns. 
FIG. 2B is a graph of estimates of DNA quantity in the 
positive control sample in Profiler Plus and Identifiler STR 
typing kits. The vial of positive control DNA sample supplied 
with STR typing kits from Applied Biosystems was used as a 
quantitation control in each Q-TAT assay. Quantity estimates 
obtained by Q-TAT were plotted along with the quantity of 
DNA indicated on the vial in the STR typing kit. 
FIG. 3 is a graphical comparison of real time PCR and 
DNA was quantitated using a 7000SDS thermal cycler and 
the Quantifiler kit (both obtained from Applied Biosystems, 
Foster City, Calif.). 
Results 
40 Q-TAT quantitation methods with shared human DNA 
samples. A group of 10 DNA samples previously quantitated 
using real time PCR (with the Quantifiler kit from Applied 
Biosystems, Inc.) were subjected to quantitation using 
The strategy for quantifying human genomic DNA in 
extracts was to generate a standard curve of fluorescence in 
amelogenin amplicons produced from known quantities of 
input human template DNA. Highly reproducible standard 45 
curves could be produced using either male or female refer-
ence human genomic DNA (FIG. 1). Substituting female 
rather than male DNA as the quantitation standard had no 
significant effect on the concentration estimates for 
unknowns (not shown). This is likely due to the comparable 
efficiency of amplification of the amelogenin gene on the X 
and Y chromosomes. Thus, each copy of the amelogenin gene 
on each of the two X chromosomes in a female would produce 
the same amount of total amplicon fluorescence as product 
amplified from one copy of the gene on X and the other 
located on Y in the male. 
FIG. 1 is graph of standard curves produced using male 
reference DNA and Q-TAT in 10 independent assays. Stan-
dard curves were produced by amplifying 0, 31.25 pg, 62.5 
pg, 125 pg, 250 pg, and 500 pg aliquots of male reference 
DNA using the sex typing kit as described in Materials and 
Methods. Shown at each data point is the mean fluorescence 
incorporated into the X and Y amplicons from 10 separate 
assays along with error bars reflecting a coincidence of varia-
tion of approximately 25% at all concentrations of input 
reference DNA. Also shown is a best fit of the data from the 
ten separate assays (R2 =0.9751). 
Q-TAT. 
An important test of any new method is whether it passes 
validation through comparison to existing, accepted methods. 
As part of the Q-TAT validation process, Q-TAT was used to 
quantitate DNA in a cohort of samples supplied by other labs 
that had been subjected to prior quantitation using Quan-
50 tiblot® (QB) or real timePCR. The results of the comparisons 
are shown in FIGS. 2A, 2B, and 3. Comparison between DNA 
concentration estimates by QB and Q-TAT are shown as 
scatter plots in FIG. 2A. Most samples showed reasonable 
agreement in the estimates made by the two methods and 
55 there was no indication of a possible bias inherent in either 
method for estimating DNA concentration. As might be 
expected however, very low or very high concentrations of 
DNA exhibited the greatest disagreement between the two 
methods. Part of the explanation for the variation in estimates 
60 could be due to the more subjective nature of estimation using 
the QB method which directs an analyst to try and match the 
color intensity of an unknown to one of the twofold dilutions 
of the control DNA, a process very much like yield gel meth-
ods. If an unknown contained a DNA concentration lying in 
65 the middle of a two fold range bracketed by the quantitation 
standards, more variation might be expected in estimating the 
concentration of that sample. Moreover, unknowns exhibit-
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ing either very low or very high intensities of color would be 
expected to exhibit the greatest variability in concentration 
estimate in the same way as estimates made from yield gels. 
An alternate approach to evaluate the accuracy of the 
Q-TAT method is to quantify DNA contained within known 
samples. As a normal component of every Q-TAT assay, a 100 
pg aliquot of positive control DNA supplied with Profiler Plus 
or Identifiler STR typing kits was included as a "quantitation 
control". Results from 15 separate assays are shown in FIG. 
2B. The average Q-TAT estimate of DNA in these assays was 
86.2 picograms and the coincidence of variation was about 
34%. 
Shown in FIG. 3 are DNA concentration comparisons from 
real time PCR and Q-TAT. As was observed above, both 
methods produce concentration estimates that agree reason-
ably well. Interestingly, whereas concentration estimates 
from QB and Q-TAT exhibited variation that was random 
demonstrating no obvious bias, real time PCR consistently 
yielded an estimate that was higher than Q-TAT (FIG. 3). 
It is also imperative for any method used for DNA quanti-
tation to be reproducible. The coincidence of variation calcu-
lated for repeated measurements of DNA in a total of 10 
samples (40 measurements) containing approximately 0.5-
1.0 ng/ul using Q-TAT and 7 samples (28 measurements) in 
the 0.1 ng/ul range was about 35%. This is comparable to the 
reproducibility exhibited by Quantiblot® technology (not 
shown). 
Discussion 
16 
difference between the two assays, and one advantage of 
Q-TAT, is that the technique quantitates fluorescence in PCR 
products from the X and Y chromosomes which creates the 
potential for identifying male:female mixtures of DNA 
5 present in extracts from forensic evidence. At a minimum, 
Q-TAT can suggest a male:female mixture of DNA is present 
in an extract, and with sufficient validation, it may be possible 
to use Q-TAT to estimate the relative proportions of male and 
female DNA in a mixed sample. 
10 A new and rapidly growing technology for the quantitation 
of human DNA is real time PCR (8,10-12). Primers exist for 
several loci, including the X and Y chromosome, that make 
the amplification specific for primate DNA, and the incorpo-
15 ration of intercalating dyes into PCR product at the end of 
each PCR cycle, or the cleavage of quenched fluors attached 
to primers through a Taq-man strategy allows for quantitation 
of product buildup (8,10-12). Sensitivity ofreal time PCR is 
better than Q-TAT and the dynamic range is much higher 
20 because quantity estimates are in part based upon the slope of 
the rate of increase in PCR product with each successive 
round of amplification. Therefore, in amplifications contain-
ing a high concentration of DNA template, early rounds of 
amplification would demonstrate a dramatic rate of increase 
25 in PCR product and an accurate estimate of template quantity 
could be made after early rounds of the cycling program 
before primers and other reactants become limiting. Q-TAT 
technology, on the other hand, requires all cycles to be com-
pleted before quantitation occurs. For samples with a high 
30 
concentration of DNA, reactants could become limiting mak-
ing accurate quantitation impossible. Analysts must therefore 
examine concentration estimates from extracts demonstrat-
ing a high concentration of DNA carefully and perhaps re-
Quality assurance standards upon which audits by 
ASCLAD-LAB and NFS TC are based mandate the quantita-
tion of human DNA recovered from any evidentiary items 
subjected to STR analysis in the forensic laboratory. Reasons 
for the mandate revolve around ensuring the quality of the 
DNA-STR profiles produced since currently available multi-
plexes are affected by the quantity of input human DNA 
template (1-3). Since most items of biological evidence will 
serve as a growth substrate for micro-organisms, DNA quan-
titation methods that are not specific for human DNA and will 
not accurately quantify the amount of human template 
present in an extract that may also contain non-human DNA. 
An additional reason to quantify human DNA in an extract 
relates to the preservation of as much template as possible for 
repeat testing by another laboratory, should that be requested 45 
by the court. 
35 quantitate the sample(s) using a dilution series to get an 
accurate estimate of the DNA present. While this may appear 
to be a significant limitation of the Q-TAT methodology, in 
our experience, analysts can incorporate features of an evi-
dentiary sample being extracted into a theoretical estimate of 
40 how much DNA will be recovered from that sample and 
bracket a useful template input initially using several dilu-
tions of the unknown to obtain a reliable estimate of DNA 
concentration. In fact, a lab may wish to amplify 2-3 dilutions 
of every unknown as a standard procedure. Amplifying a 
small dilution series can also reveal the presence of PCR 
inhibitors in evidentiary samples; the logic being that more 
diluted samples would reveal the presence of greater amounts 
DNA than less diluted or undiluted samples in the series. 
The Q-TAT, Quantiblot®, and real time PCR quantitation 
methods all rely on comparing the amount of DNA in an 
unknown to some well characterized (and quantitated) refer-
ence standard. In the case of Q-TAT, a standard curve con-
sisting of fluorescence contained within amelogenin products 
Current methods for quantifying human DNA include slot 
blot/probe hybridization available currently in the Quan-
tiblot® kit. This technology is one that stands alone in the 
forensic laboratory, requiring specialized methods and equip- 50 
ment not used for other procedures in a DNA section. Sensi-
tivities for Quantiblot® technology range from approxi-
mately 150 pico grams to 10 nanograms (package insert from 
the Quantiblot® kit) which is less sensitive than the Q-TAT 
technology, but which has a much broader dynamic range. 
An approach to quantifying human DNA very similar to 
Q-TAT was reported by Sifis et al. in 2002 (7). Rather than 
using fluorescence incorporated into amelogenin amplicons, 
these authors measured fluorescence incorporated into ampli-
cons amplified from the Alu family of short interspersed 60 
repeats. Like the amelogenin locus, the Alu sequences are 
primate specific thereby making the assay useful for quanti-
fying human DNA. The assay reported by Sifis et al (7) 
exhibited a useful range of 2.5-100 pg of human genomic 
DNA. This level of sensitivity is higher than the sensitivity 65 
reported here, although the upper limit of DNA that can be 
estimated is a little higher in the Q-TAT assay. The principle 
55 
amplified from different amounts of reference DNA was used 
to estimate amounts in unknowns. Although the work 
reported here was performed using a male DNA sample to 
prepare the standard curve, use of a female reference sample 
produced comparable concentration estimates as long as the 
area under both the X and Y products was summed before 
comparison to the standard curve prepared from female DNA. 
This is not surprising since single copies of the amelogenin 
locus reside on the X and Y chromosomes and are amplified 
with roughly equal efficiency. Hence, the amelogenin locus 
on the two copies of the X chromosome in a female exhibit 
molar equivalence to amelogenin loci on the single copy ofX 
and single copy ofY in the male. 
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The Q-TAT assay may also enable an estimate of male and 
female DNA in a mixed sample from a sexual assault by 
plotting on the fluorescence under the Y amplicon with com-
parison to Y amplicon fluorescence in a standard curve pre-
pared from male DNA. Such validation is planned and would 5 
further enhance the utility of Q-TAT as a quantitation tool in 
a DNA typing laboratory. 
18 
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Comparison of concentration estimates between real time 
PCR and Q-TAT indicated a consistently higher estimate 
made using real time PCR. Likewise, real time PCR consis- 10 
tently produced estimates that are higher on samples also 
tested using QB methods (not shown). In contrast, compari-
sons between Q-TAT and QB exhibited a random pattern of 
variation in concentration estimates among the shared 15 
samples. These results may indicate a bias ofreal time PCR to 
over estimate human DNA concentrations, or an under esti-
mation bias characteristic of QB and Q-TAT. In this regard, 
replicate measurements of the positive control supplied with 
STR typing kits may suggest Q-TAT underestimates DNA 
quantities. Ultimately, the requirement for any quantitation 
assay is reliability. If a quantitation method underestimates or 
overestimates human DNA, the bias can be identified through 
validation and considered when amplifying a template for 
STR results. As long as the amount of DNA template ampli-
fied reliably produces a DNA profile that is of sufficient 
quality to interpret, the limitations of the assay used to quan-
titate DNA in a sample are not so critically important. 
20 16. Micka KA, Amiott EA, Hockenberry TL, Sprecher CJ, 
Lius AM, Rabbach DR. TWGDAM validation of a nine-
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EXAMPLE2 
Q-ACE Total Human and Male-Only DNA 
Quantitation Procedure: Combined Q-TAT and 
Capillary Electrophoresis 
The procedure that follows has been developmentally vali-
dated and internally validated by the Tulsa Police Department 
Forensic Laboratory Biology Section. 
40 Background Information: 
Knowing the approximate human DNA concentration 
within extracted forensic evidence samples facilitates suc-
cessful DNA amplification for the purpose of forensic DNA 
45 profiling and is mandated by Standard 9.4 of the QAS (Qua!-
50 
ity Assurance manual). This requirement stems from the fact 
that forensic DNA evidence is generally of an extremely 
limited nature and that, whenever possible, at least halfof this 
limited sample should be retained for future re-testing. Accu-
rate quantification methods performed pre-DNA profiling 
help to ensure that optimal DNA profiling results will be 
obtained within one round of testing and that the maximum 
7. Walsh P, Varlaro J, Reynolds R. A rapid chemiluminescent 55 
method for quantitation of human DNA. Nucl Acids Res 
1003; 20:5061-5065. 
amount of evidence will remain for further testing. The Biol-
ogy Section uses a sex-typing PCR-based multiplex 
described in Example 1 as Quantitative Template Amplifica-
tion Technology (Q-TAT). This Examples describes quanti-
tative analysis of the Q-TAT multiplex using capillary elec-
trophoresis (CE). This combined methodology is referred to 
8. Nicklas J A, Buel E. Development of an Alu based, real-
time PCR method for quantitation of human DNA in foren-
sic samples. J Forensic Sci 2003; 48:936-944. 
9. Sifis ME, Both K, Burgoyne L.A. A more sensitive method 
for the quantitation of genomic DNA by Alu amplification. 
J Forensic Sci 2002; 47:589-592. 
60 as Quantitative Amplification through Capillary Electro-
phoresis (Q-ACE). The Q-ACE method allows for picogram 
(pg) ( one-trillionth of a gram) amounts of human DNA to be 
quantified by use of DNA-specific primers to the human X 10. Nicklas J A, Buel E. Development of an Alu based, QSY7-
labeled primer PCR method for quantitation of human 65 
DNA in forensic samples. J Forensic Sci 2003; 48:282-
291. 
and/or Y chromosomes. A set of additional primers allows the 
amplification of an internal positive control (IPC). The fol-
lowing targets are amplified: 
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TABLE 1 
Arn lilied tar els. 
Arnplicon approximate size migration 
size in after addition of FAM dye 
Target Target information Location bases tag on reverse primer only 
SRY sex-determining Ypll.3 111 109 
region Y gene 
!PC the pRL null 
plasmid from 203 200 
Renilla luciferase 
(sea pansy) 
X arnelogenin X Xp22.31- 212 209 
p22.1 
y arnelogenin Y Ypll.2 218 216 
The dynamic range of quantitative fluorescent detection by National Institute of Standards and Technology Standard 
Reference Material (NIST SRM) 2372 human DNA quanti-
tation standards (purchased from NIST) 
20 FAM dye labeled primers (purchased from Invitrogen) as 
depicted in Table 2. 
a CE device is measured in relative fluorescent units (RFU). 
RFU, for the purpose of this procedure, is expressed as a peak 
height value. The linear range for quantitative CE is from 
about 150RFU to approximately 6000RFU. These detected 
RFU values are representative of an amount of fluor-labeled 
DNA product passing the detector. Although the actual 
amount of DNA passing by the detector is unknown, but the 
25 
amount of DNA pre-amplification ( and pre-CE analysis) can 
be known for standard samples. When observing the detected 
RFU values of a standard curve made from a known quantity 
of female or male standard DNA, we have determined that the 
amount of DNA pre-amplification in a sample is directly 30 
proportional (R2=1) to the detected peak height RFU of this 
sample during CE detection. Based upon this proportional 
relationship, the CE quantitative linear range stated above as 
150RFU to 6000RFU has been determined to correspond to a 
pre-amplification DNA amount of between 35 pg to 700 pg. 35 
However, this range will fluctuate for every CE device 
because each device has different detectors with differing 
dynamic ranges of detection. With this knowledge, the 
amount of DNA in an unknown sample can be directly deter-
mined from the observed peak height of that sample collected 40 
during QCE. 
Above 500-700 pg DNA, the fluorescence levels may 
become so great that the detector is overwhelmed. This level 
of fluorescence is known as the limit oflinearity (LOL) of the 
45 device's detector. Thus, >700 pg DNA cannot be accurately 
quantified in undiluted form by a CE device. However, one 
can re-amplify unknown samples exhibiting> 700 pg of DNA 
in a diluted form and then determine the fluorescence of the 
post-amplification DNA sample. When coupled with the abil- 50 
ity to dilute an unknown DNA sample, CE detection has a 
dynamic quantitative range of 0.063 ng/uL to unlimited 
ng/uL. 
INSTRUMENTATION: Pipetman P-1000, P-200, P-100, 
P-20, P-10, USA Scientific Mini-Fuge Centrifuge, ABI Prism 55 
310 Genetic Analyzer and its ancillary equipment, Labconco 
Protector Fume Hood, Millipore Elix-S Purification System, 
Millipore Milli-Q Purification System, Compact Refrigera-
tor, Compact Freezer, Napco 8000-DSEAutoclave,ABI 9700 
thermal cycler, Temperature Verification Kit, Mini-Max II 60 
vortexer, anABIApple-based or PC-based GeneScan or Gen-
eMapperID software. 
Reagent Preparation: 
TABLE 2 
FAM dye labeled primers 
Primer name Sequence 
AMEL 
forward 
AMEL 
reverse 
5'-ACC TCA TCC TGG GCA CCC TGG-3' 
5'-AGG CTT GAG GCC AAC CAT CAG-3' 
FAM 3' -TCC GAA CTC CGG TTG GTA GTC-5' 
SEQ 
ID 
NO, 
1 
2 
SRY forward 5'-ACG AAA GCC ACA CAC TCA AGA AT-3' 3 
SRY reverse 5' -CTA CAG CTT TGT CCA GTG GC-3' 4 
FAM 3' -GAT GTC GAA ACA GGT CAC CG-5' 
pRL forward 5' -~G GTG GTA AAC CTG ACG TTG-3' 5 
pRL reverse 5' -TTC ATC AGG TGC ATC TTC TTG-3' 6 
FAM 3' -AAG TAG TCC ACG TAG AAG AAC-5' 
Lab-Generated Solutions: 
A NIST female DNA dilution series; 2)A NIST male DNA 
dilution series 3) Sterile dH20 
Procedure for Preparing the Q-ACE Three Primer Mix: 
When the six primers (3 primer pair sets) are received from 
Invitrogen, they will be combined into primer pair sets in the 
lab. Q-ACE Three Primer Mix Worksheet must be filled out 
for this procedure. Such a worksheet should include at least 
the following entries related to the primers: name, nmole 
amount, status, µl needed for 1 00x, final total of µl of primer 
pair, and number of 1 and/or 10 µl aliquots. In addition, the 
worksheet should contain the date, analyst initials, and lot 
number(s) of buffer(s) used. Record the nmole amount of 
dried primer in each primer tube from the packing slips. 
Staple these slips to the back of the worksheet. 
Prepare the Q-ACE three primer master mix as per work-
sheet instructions, reproduced below. Log the information 
into the chemical inventory. The Q-ACE three primer mix 
must contain a final concentration of 1 Ox amelogenin primer 
set, 1 0xSRY primer set, and 1 xpRL primer set in sterile 
dH20. 
Purchased Solutions: 
pRL null vector (purchased from Promega Part #E2271) 
2xGo-Taq Colorless DNA polymerase mixture (purchased 
from Promega Part #M7133) 
Instructions for Preparation ofQ-ACE Three Primer Master 
65 Mix 
Record nmole amount for each primer. Calculate how 
many µl of liquid is needed to rehydrate a l00x solution of 
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that primer. NOTE: If 53.8 nmoles of dried primer has been 
received, then you would add 538 µl ofliquid to that primer to 
rehydrate l00x solution of that primer). Record the µl of 
liquid needed above. Determine which primer in each pairing 
has been received in the largest nmole quantity and in the 5 
smallest nmole quantity. Record a star for the largest one of 
each pair in the "status" colunm. Begin primer rehydration by 
making a 1 00x solution out of the "largest" primer in the pair 
using TE Buffer. Mix this solution very well. Now use this 
single primer solution instead of TE Buffer to rehydrate the 10 
"smallest" primer in the pair at 1 00x. In this way, both prim-
ers in a pair are resuspended at l00x together and this proce-
dure makes a l00x solution of each primer pair. Record the 
final volume of each 1 00x primer pair in the appropriate row 
above. Now, use the l00x primer pairs to make as much TPM 15 
as possible. For every 100 µl ofTPM, you must mix 100 µl of 
1 00xAMEL primer set+ 10 µl of 1 00xSRY primer set+ 1 µl of 
1 00xpRL primer set+ 79 µl dH20. Determine how much total 
TPM can be made from the primer sets above to completely 
consume the primer sets if the AMEL or SRY is the limiting 20 
primer set. Make the TPM in bulk and record the TPM lot 
number (six-digit date plus three letter initials) on the work-
sheet. Dispense the TPM into 300 µl aliquots and store frozen 
at -20° C. in a labeled tube rack. Use only one aliquot at a 
time. The aliquot in use can be thawed and stored at 4 ° C. until 25 
consumed. Place the worksheet in a Chemical Logbook 
Binder. The worksheet acts as a CHEMICAL LOGBOOK 
SHEET for the primers, primerpairs, and the TPM used in the 
Q-ACE procedure. 
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Step 6: Make sure the worksheet is completely filled out. 
Place the GeneAmp PCR tubes into the thermal cycler. Run 
the Q-ACE amplification cycle with the following sub-parts: 
TABLE3 
Q-ACE amplification cycle 
Sub-program Type Temperature Time 
CYCLE (30) 98° C. 10 sec 
55° C. 60 sec 
72°C. 30 sec 
HOLD 60° C. l0min 
HOLD 25° C. 00 
Step 7: After amplification, prepare each sample for 310 
analysis by following the 310 analysis procedure for Q-ACE 
samples on the worksheet. Include a 310 blank (seethe "ABI 
Prism 310 Genetic Analyzer Capillary Electrophoresis Pro-
cedure"). No allelic ladder is needed for Q-ACE. Because the 
amplified products are labeled with the blue FAM dye, you 
may click only for LIZ-orange and FAM-blue to be collected 
on the five-dye sample sheet. Fill in Q-ACE sample tracking 
numbers. Make an injection list from the sample sheet. Make 
sure the sample sheet and injection list contain "Q-ACE" in 
the title and identify the particular 310 instrument in the title. 
Make sure that the run-time parameters are changed so that 
electrophoresis is 21 minutes. This reflects the minimum time 
it takes for Q-ACE peak data to be collected. Observe, record, 
Procedure for Making a NIST Standard Dilution Series: 30 and analyze data using 310 ABI Prism Collection Software 
version 2.1, GeneScan Analysis 3.1.2 Software, and the 
"Q-ACEfiler" genotyping macro, lovingly handcrafted by 
Jonathan P. Wilson. Print out the Q-ACEfiler EP's. 
Label six microcentrifuge tubes A-1000 pg/µL, A-500 
pg/µL, A-250 pg/µL, A-125 pg/µL, A-63 pg/µL, and A-32 
pg/µL. Label six microcentrifuge tubes B1000 pg/µL, B 500 
pg/µL, B-250 pg/µL, B-125 pg/µL, B-63 pg/µL, and B-32 
pg/µL. Determine the nano gram amount (#)of male DNA per 35 
µL residing in the NIST A Standard tube. Add 1 µL of the 
NIST A Standard DNA totheA-l000pg/µL tube and then add 
(#)-1 µL of sterile dH20 to theA-l000pg/µL tube.Add 25 µL 
of sterile dH20 to the rest of the A-series tubes. Add 25 µL of 
tubeA-1000 pg/µL solution to tubeA-500 pg/µL to make 50 40 
µL of a 500 pg/µL NIST A DNA solution. Add 25 µL of tube 
A-500 pg/µL solution to tube A-250 pg/µL to make 50 µL of 
a 250 pg/µL NIST A DNA solution. Add 25 µL oftubeA-250 
pg/µL solution to tube A-125 pg/µL to make 50 µL of a 125 
pg/µL NIST A DNA solution. Add 25 µL oftubeA-125 pg/µL 45 
solution to tubeA-63 pg/µL to make 50 µL of a 63 pg/µL NIST 
A DNA solution. Add 25 µL of tube A-63 pg/µL solution to 
tube A-32 pg/µL to make 50 µL of a 32 pg/µL NIST A DNA 
solution. Make the NIST B DNA Dilution Series similarly. 
Procedure for Making a Female and Male NIST Standard 50 
Curve for a Particular 310 CE Device: 
Step 8: Plot the Q-ACEfiler RFU data on a Q-ACE Stan-
dard Curve excel worksheet. A female standard curve must be 
plotted when estimating the amount of total human DNA 
needed for successful genomic DNA profiling (ie. Identfiler 
profiling). A female standard curve must be made by plotting 
the Amelogenin X amplicon fluorescence values against the 
corresponding known NIST B pg amount in each tube pre-
amplification. 
Step 9: Store the Standard Curve as an excel file named 
"MMDDYY-FML-(old/new)310-(male or female)". When 
Q-ACE data is gathered from unknown DNA samples using a 
310 CE device, the pg DNA amount in those unknown 
samples must be calculated using a standard curve generated 
from the very same 310 CE device. The standard curves will 
be specific to each 310 device. Note that some 310 devices 
have a more or less sensitive dynamic range of RFU detection 
than other 310 devices (each CCD detector is different). To 
compensate for a lower LOL in some CE devices, the injec-
tion time for the standard curve samples and the unknown 
samples can be decreased from 5 seconds down to one sec-
Step 1: Record all information for this procedure onto a 
Q-ACE Amp Set-up and 310 Set-up Worksheet. Prepare the 
Q-ACE master mix. The recipe for this master mix is on the 
Q-ACEAmplification Set-Up Worksheet. The Q-ACE master 
mix in its final form must contain 1.2xDNA polymerase and 
buffer. 
Step 2: Label thirteen total GeneAmp PCR tubes according 
to the worksheet. Six tubes must be labeled for each NIST A 
55 ond. The data gathered at an initial 5-second injection time 
will allow the analyst to decide if subsequent data must be 
gathered at a decreased injection time. Whatever the outcome, 
the injection time used to generate the standard curve for that 
Serial Dilution and six tubes must be labeled for each NIST B 60 
CE device must be the same as the injection time used to 
calculated the DNA content of unknown samples for that 
standard curve on that specific CE device. Serial Dilution. One Q-ACE negative control blank tube must 
be labeled. 
Step 3: Add 11.5 µl of appropriate master mix to each tube. 
Step 4:Add 1 µlofeachoftheNIST AandB dilutions to the 
appropriate amp tube. 
Step 5: A Q-ACE negative control blank tube must be made 
by adding 1 µL sterile dH20 to the appropriate amp tube. 
CONTROL RESULTS FOR STANDARD CURVES: 
Check the accuracy and precision of a male or female stan-
dard curve CONTROL RESULTS below) by the following 
65 conditions: 
R 2 value of the line ofregression must be between 0.97 and 
1.00 
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the line of regression must have a slope that causes the 
Y-intercept value to fall below 150 RFU 
when the Limit of Quantification (LOQ) for the CE instru-
ment ( also referred to as the minimum interpretation 
threshold "MIT") is theoretically plugged in as 150 5 
RFU, the test pg amount calculated using the standard 
curve must approach 35 but never exceed 35. 
when the Limit of Detection (LOD) for the CE instrument 
(also referred to as the peak amplitude threshold "PAT") 
is theoretically plugged in as 50 RFU, the test pg amount 10 
calculated using the standard curve must not exceed 0. 
A female standard curve must be calculated from the NIST 
24 
you may click only for LIZ-orange and FAM-blue to be 
collected on the five-dye sample sheet. Fill in Q-ACE sample 
tracking numbers. Make an injection list from the sample 
sheet. Make sure the sample sheet and injection list contain 
"Q-ACE" in the title and identify the particular 310 instru-
ment in the title. Make sure that the run-time parameters are 
changed so that electrophoresis is 21 minutes. This reflects 
the minimum time it takes for Q-ACE peak data to be col-
lected. Make sure that a female and/or male standard curve is 
available for the CE instrument used. Make sure that the 
samples are injected for the same time as the injection time 
used to generate the standards curve. Observe, record, and 
analyze data using 310 ABI Prism Collection Software ver-
sion 2.1, GeneScan Analysis 3.1.2 Software, and the B female DNA dilution series using the Amelogenin "X" 
amplicon's RFU values. The female standard curve must be 
used to calculate the amount of DNA in an unknown sample 
for later amplification using a genomic DNA profiling kit (ie. 
identifiler, Minifiler, Profiler, COfiler, etc.) A male standard 
curve must be calculated from the NIST A male DNA dilution 
15 "Q-ACEfiler" genotyping macro. Print out the Q-ACEfiler 
EP's. 
series using the SRY amplicon's RFU values. The male stan- 20 
dard curve must be used to calculate the amount of DNA in an 
Step 9: Plot the Q-ACEfiler RFU data for the unknown 
samples on a Q-ACE Standard Curve excel worksheet. The 
appropriate female standard curve data must be used to esti-
mate the amount of total human DNA needed for successful 
genomic DNA profiling (i.e. Identfiler or Minifilerprofiling). 
The appropriate male standard curve data must be used to 
estimate the amount of human male-only DNA needed for 
successful male haplotype DNA profiling (i.e. Yfiler profil-
unknown sample for later amplification using a male haplo-
type DNA profiling kit (ie. Yfiler). A new standard curve will 
have to be generated at least once a year or after any incidence 
of maintenance or use of a new matrix for that instrument. 
Procedure for Estimating the Amount of Total Human or 
Human Male-Only DNA in an Unknown Sample for a Par-
ticular 310 CE Device: 
25 ing). The worksheet auto-populates the estimated DNA 
amounts in the unknown samples. The Q-ACE female and 
male estimated pg/µL value is within a range of pg/µL values 
that have been determined to be less than a% CV of 30. Peaks 
Step 1: Record all information for this procedure onto a 
Q-ACE Amp Set-up and 310 Set-up Worksheet. Prepare the 30 Q-ACE master mix. The recipe for this master mix is on the 
Q-ACEAmplification Set-Up Worksheet. The Q-ACE master 
mix in its final form must contain 1.2xDNA polymerase and 
buffer. 
must be apparent in the NIST-traceable female and NIST-
traceable male Q-ACE positive controls for all relevant 
amplicons in the QTAT assay as described in the Table in the 
Background Information section of this procedure. Inform 
and consult the Biology Section Technical Leader if these 
conditions are not met or if concerns about the male DNA 
Step 2: Label GeneAmp PCR tubes according to the work-
sheet. Tubes must be labeled for the NIST A 250 pg/µL Serial 
Dilution, the NIST B 250 pg/µL Serial Dilution, and one 
Q-ACE negative control blank. 
35 control arise. The negative QTAT control (blank) should only 
have an IPC peak present. See Appendix for how acceptable 
QTAT controls should appear. 
Step 3: Add 11.5 µl of appropriate master mix to each tube. 
Step 4: Add 1 µl of each of the NIST A 250 pg/µL male 
positive control sample, NIST B 250 pg/µL female positive 
control sample dilutions to the appropriate amp tubes. 
Step 10: Print out the appropriate completed Q-ACE Stan-
dard Curve worksheet(s) to include in the casefile. Once 
40 printed, the data does not need to be stored electronically. 
Step 5: Make the Q-ACE negative control blank tube by 
adding 1 uL sterile dH2O to the appropriate amp tube. 
Step 6: Make the Q-ACE samples to be quantified by 45 
adding 1 µL of the appropriate unquantified sample to the 
appropriate amp tube. 
Step 7: Make sure the worksheet is completely filled out. 
Place the GeneAmp PCR tubes into the thermal cycler. Run 
the Q-ACE amplification cycle with the following sub-parts: 50 
TABLE4 
Q-ACE amplification cycle 
Sub-program Type Temperature Time 55 
CYCLE (30) 98° C. 10 sec 
55° C. 60 sec 
720 C. 30 sec 
HOLD 60° C. l0min 
HOLD 25° C. 00 60 
Step 8: After amplification, prepare each sample for 310 
analysis by following the 310 analysis procedure for Q-ACE 
samples on the worksheet, including a 310/CE blank (seethe 
"ABI Prism 310 Genetic Analyzer Capillary Electrophoresis 65 
Procedure"). No allelic ladder is needed for Q-ACE. Because 
the amplified products are labeled with the blue FAM dye, 
Step 11: Print out the appropriate completed Q-ACE Stan-
dard Curve worksheet(s) to include in the casefile. Once 
printed, the data does not need to be stored electronically. 
Important Testing Considerations: 
During developmental validation we determined that the% 
CV for any particular CE device's electrophoretic injec-
tion and fluorophore detection is achievable at less than 
1 % if the instrument is carefully set-up. The integrity of 
the closed system for electrophoresis (i.e. the "block") is 
the most critical factor in keeping the % CV low for the 
CE instrument. If the "block" is more than two to three 
days old or has had a buffer change without a capillary 
change, the % CV can increase to over 10%. Once an 
instrument is set up, the buffer that originally has circu-
lated through the polymer in the system should not be 
changed or re-hydrated until quantitative CE (QCE) data 
is completely gathered. The "block" can be re-hydrated 
or rejuvenated according to each laboratory's own poli-
cies regarding qualitative DNA analysis (i.e. regular 
allele size-typing). We have demonstrated that QCE is 
sensitive to "block integrity", whereas qualitative CE 
used to size-profile alleles is not (not shown). 
During developmental validation the % CV for pipetting 
and dilution was determined to be less than 1 %. Using a 
pipetting device to measure out less than 1 µl ofliquid is 
not acceptable, due to the limitations of the pipetting 
device. This is why the dilution schemes and recipes are 
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laid out the way they are. Pipetting less than 1 µl ofliquid 
will raise the % CV above 1 %. 
If a Q-ACE sample has truncated peaks in the null dilution 
and truncated peaks in the ½sth dilution, then too large 
26 
evidence (2). This requirement stems from the fact that foren-
sic DNA evidence is generally of an extremely limited nature 
and that, whenever possible, at least half of this limited 
of an original sample has been taken. For example, a 5 
DNA extract with QTAT-QCE value of 20 ng/µl means 
that enough DNA to run 20 separate DNA amplifications 
was isolated in this sample. In theory, this would mean 
that at least 20 times more evidence or original sample 
was consumed than was necessary to obtain a DNA 10 
profile. If a sample has more DNA than this, it is con-
sidered wasteful. The analyst should, at this point, make 
sample should be retained for future re-testing. Accurate 
quantification methods performed pre-DNA profiling help to 
ensure that optimal DNA profiling results will be obtained 
within one round of testing and that the maximum amount of 
evidence will remain for further testing or future re-testing. 
As a result of the limited nature of forensic DNA evidence, 
many DNA quantification methods have recently arisen, 
evolved, and changed in order to provide additional informa-
tion beyond a mere estimation of DNA concentration. Ideal 
forensic DNA quantification methods should be human-spe-
cific so that DNA profiling will not be attempted on non-
human DNA samples. Ideal forensic DNA quantification 
methods should be very sensitive and also provide informa-
tion concerning levels of chemical inhibitors or DNA degra-
dation that may be present in a forensic sample. Non-human-
specific DNA quantification methods like spectrophotometry 
an effort to better estimate the density of the original cell 
content of the sample being tested so that samples this 
concentrated are not routinely isolated. Consult with the 15 
Biology Section Technical Leader to improve proper 
sample size estimation. If it does occur, however, that a 
sample has Q-ACE results greater than 20 ng, then it is 
acceptable for the analyst to dilute that sample more and 
then repeat quantitation. 20 or fluorometry are no longer widely considered able to pro-
vide enough information because they are not human specific. 
Although the yield gel can provide information concerning 
DNA degradation, its level of sensitivity and its inability to 
Special handling needs are required for Hi-Di formamide. 
Opened Hi-Di formamide is to be kept in lab three. 
Formamide may act as a potential teratogen when 
inhaled or absorbed into the skin. All analyzed samples, 
tubes, and pipette tips containing formamide waste are 25 
to be placed into 50-ml Falcon tubes for disposal into the 
biohazardous waste receptacles. In this way, formamide 
vapor/fumes are minimized. 
provide any other specific information overshadows the infor-
mation it does provide about DNA samples. Quantitative 
DNA hybridization techniques have been able to provide 
human specificity and a greater level of sensitivity, but have 
not been able to provide information concerning inhibition or 
degradation, which may explain the demise of one quantita-
tive DNA hybridization method utilized by many forensic 
DNA laboratories, QuantiB!ot® (Applied Biosystems, Foster 
The use of refrigerated instead of frozen Hi-Di formamide 
was developmentally validated for the Q-ACE proce- 30 
dure without any adverse effect on data quality. 
CONCLUSION: Use of the foregoing protocols resulted in 
rapid, accurate, reliable determination of the quantity, quality, 
gender of origin and presence or absence of PCR inhibitors 
for all samples tested. 
EXAMPLE3 
A method for simultaneously quantifying the amounts of 
human and male-only DNA within a sample by amplification 
of that sample with fluorophore-tagged human-specific DNA 
primers was described in Example 1 (1). Post-amplification, 
the fluorescent peak heights of the products of amplification 
can be quantified using capillary electrophoresis with fluo-
rescent detection. Amounts of peak height fluorescence can 
then be used to determine the amount of DNA residing in an 
unknown sample pre-amplification by comparison to a stan-
dard curve of peak height fluorescence created from the 
amplification of DNA solutions of known quantity (1). 
Because this method employs the amplification of gender-
specific amplicons, the DNA quantity, gender, and/or relative 
amount of male and total human DNA can be simultaneously 
determined from 1 µl of any unknown DNA sample. In this 
study, we present the developmental validation of an 
improved multiplex version of the original assay that incor-
porates two more amplicons. The improved assay continues 
to accurately quantify total human and male-only DNA in 
samples while demonstrating increased sensitivity for detect-
ing male DNA within forensic mixtures. These improvements 
result in an assay that can simultaneously gender-type and 
quantify the male and total human DNA content of forensic 
unknown samples using only amplification and capillary 
electrophoresis with fluorescent detection. 
Introduction 
Human DNA quantification is now a mandatory require-
ment for all forensic laboratories within the United States that 
perform DNA-typing of human DNA samples from criminal 
City, Calif.). Quantification methods employing qPCR with 
DNA concentration estimates made either real-time (3-7) or 
post-amplification (1, 8) can provide human specificity, sen-
35 sitivity, and information regarding degradation and inhibi-
tion. The ability to detect the presence of chemical inhibitors 
in a forensic DNA sample is invaluable in that it allows steps 
to be taken to further purify the DNA sample before DNA 
profiling is attempted. Varying methods of real-time qPCR 
40 can provide this information as well as more information 
concerning the gender or mixture status of the human DNA 
within some samples. But, until recently, separate tests had to 
be performed to obtain total human quantification informa-
tion and then male-only quantification information. The 
45 introduction of flourophore-quenching technology (9) to 
qPCR technology has recently overcome the need for sepa-
rate tests for gender and mixture assessment during DNA 
quantification by making it possible to multiplex during real 
time qPCR. Recently, the Plexor™ HY qPCR System 
50 (Promega Corporation, Madison, Wis.) became the first com-
mercially available real-time qPCR system capable of simul-
taneously quantifying total human and male-only DNA 
within a DNA sample. It also follows that ideal quantification 
methods should decrease the time of analysis, increase the 
55 ease of analysis by being amenable to the current trend 
towards the automation of forensic DNA analysis, and even 
decrease the cost of analysis. Finally, the most ideal DNA 
quantification method would provide one more level of infor-
mation to the forensic DNA analyst-the ability to direct 
60 DNA profiling by predicting the success or the futility of 
various types of DNA profiling options. Several quantifica-
tion methods exist that can inform the analyst about the male 
DNA content of a forensic sample (10, 11, 12). Whether the 
information is obtained within one or two rounds of testing, 
65 the information provided by the use of primers specific to the 
X and/or Y chromosomal material within human DNA 
samples during quantification can generate information that 
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may greatly facilitate an analyst's decision to proceed with 
genomic DNA-profiling or male-only DNA profiling (13). 
Knowing gender-specific information about a sexual assault 
sample, for instance, would allow the analyst to be able to 
reasonably expect that a Y-chromosomal specific DNA pro- 5 
filing procedure would yield successful results on this 
sample. However, a quantification method that could let the 
analyst know that a forensic sample does not contain enough 
male DNA for successful profiling with the detection sensi-
tivities currently available in varying DNA testing kits would 10 
be even more valuable. Information of this nature would 
DNA profiling. In other words, it only required basic poly-
merase chain reaction (PCR) and the ability to analyze the 
amplification products using CEFD. All other quantification 
methods, to date, require the mastery of technologies other 
than basic PCR and CEFD only. PCR and CEFD are already 
required for the DNA profiling step, so no new equipment or 
supplies would be needed. Because no new equipment or 
supplies would be needed to implement this quantification 
method, the time involved in general quality assurance prac-
tices and quality control activities would dramatically 
decrease. In other words, all of the ancillary consumable 
allow an analyst to stop further analysis on that sample, thus 
saving the time and resources most analysts now spend on 
attempting DNA profiling techniques on samples that, with 
current technology, will not yield case-solving DNA profiling 
results. 
A post-amplification qPCR assay which was referred to as 
Q-TAT ( quantitative template amplification technology) was 
described in Example 1 (1 ). This assay (which we refer to here 
as the original assay) quantifies the amount of human and 
male-only DNA in a sample by amplification of the Amelo-
genin locus on the X and Y chromosomes by the use of 
fluorophore-tagged human-specific DNA primers (1). Post-
amplification, the peak height of the resulting 212-basepair 
X-amplicon and the 216-basepairY-amplicon (if present) is 
quantitatively analyzed by determining the relative fluores-
cence peak height of each amplicon using a capillary electro-
phoresis device coupled with fluorescent detection (CEFD). 
The peak height fluorescence of the X amplicon or the X and 
Y amplicons can then determine the amount of DNA residing 
in the unknown sample pre-amplification by comparison to a 
standard curve of peak height fluorescence gathered from a 
standard dilution of a male or a female DNA sample ofknown 
quantity (1 ). Because this method amplifies the X amplicon or 
the X andY amplicons oftheAmelogenin locus, the genderor 
mixture status of the unknown DNA sample can be deter-
mined at the same time as the relative amounts ofY-chromo-
somal material (the amount ofY amplicon fluorescence) and 
relative amounts of total human chromosomal material (the 
amount of X amplicon fluorescence plus the amount of Y 
amplicon fluorescence) are determined. This information can 
be obtained by the consumption of only 1 µl of any unknown 
DNA sample. In this study, we present the developmental 
validation of an improved multiplex version of the original 
assay. 
We developmentally validated an improved multiplex 
assay based upon the original assay (1) in our laboratory by 
necessity. Prior to our decision to try to implement the origi-
nal assay, we were using the QuantiB!ot® method supplied 
by Applied Biosystems to meet the quantification standard. 
When Applied Biosystems announced that it would be dis-
continuing the QuantiB!ot® Kit, the prospect of performing a 
developmental validation on this method for use in the Tulsa 
Police Department Forensic Lab Biology Section suddenly 
seemed less daunting. By April of 2007, we decided that the 
advantages of the original assay would be worth the time and 
potential expense of developmental validation. In summary, 
the original assay's advantages were as follows. The original 
assay could provide simultaneous quantification information 
concerning the total human DNA in an unknown sample as 
well as the Y-only DNA in an unknown sample. No other 
method at the time could do this. Currently, the only commer-
cially-available quantification method able to perform simul-
taneous total human and Y-only information is the Plexor™ 
HY qPCR System (Promega Corporation, Madison, Wis.) 
released in August of 2007 (11 ). The original assay required 
no additional technology other than that needed for human 
supplies and reagents would not be purchased or generated 
for this method and therefore would not need to be tracked, 
logged, and handled according to stringent national quality 
15 assurance standards. And, finally, it appeared that this assay 
would be easily amenable to automation. 
The original assay did, however, have some distinct disad-
vantages that would have to be overcome before our labora-
tory could use the procedure on actual casework. The follow-
20 ing disadvantages would have to be addressed by our 
developmental validation. The original assay as published 
had a coefficient of variation (CV) of about thirty percent that 
was not characterized or understood. The original assay, as 
published, relied heavily upon sample analysis using CEFD, 
25 but the effect of the dynamic range of the CEFD device on the 
reported quantification values had not been addressed. These 
effects would need to be completely determined and con-
trolled for prior to using the assay on actual casework. The 
effect ofutilizing differing CEFD devices had not been evalu-
30 ated and the generation of standard curve data was not stan-
dardized. The original assay could not detect the presence of 
PCR inhibitors nor could it provide accurate gender-typing or 
Y-only quantification values if the Amelogenin Y template 
present in a sample DNA extract had a primer-binding site 
35 mutation sufficient to stop primer annealing. And finally, once 
the original assay contained the multiplex of additional prim-
ers required for the detection of inhibition and the fail-safe 
ability to detect male DNA in a sample, the original amplifi-
cation parameters would need to be optimized for the 
40 improved multiplex assay. 
The developmental validation of an improved multiplex 
assay presented here has resulted in an improved multiplex 
assay that has overcome all of the disadvantages of the origi-
nal assay. The original assay (1) has been modified to include 
45 two additional fluorophore-tagged primer sets and a non-
human DNA target. One of the added primer sets flanks the 
SRY gene (14, 15) which maps to the human Y-chromosome 
Ypl 1.3 (12,16). The single 111-basepair amplicon resulting 
from amplification with this primer set allows for two major 
50 improvements in the original assay. 1-2% of males have 
mutations in the Y-chromosomal Amelogenin gene (17). In 
certain males, the original assay may not exhibit a detectable 
Amelogenin Y amplicon. Together, the Amelogenin Y and 
SRY amplicons provide redundant indicators of"maleness", 
55 thus controlling for male primer-binding mutations at a 
greater level than the original assay. Furthermore, the addi-
tion of the SRY primer set dramatically increases the sensi-
tivity of detection of male DNA in unknown samples. The 
Amelogenin primer set from the original assay amplifies a 
60 diploid DNA target. In females, this target is homozygous (X, 
X) and in males this target is heterozygous (X, Y). The SRY 
primer set in the improved assay amplifies a haploid target 
only in males. Because there is no homologue to SRY on the 
X chromosome, the SRY target has less chance of stochastic 
65 "dropout" during amplification in the presence of female 
DNA. As a result, theAmelogenin amplicons in a mixture are 
better predictors of genomic DNA profiling success, while 
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the SRY amplicon is a better predictor of DNA haplotype 
profiling success. The other added primer set amplifies a 
200-basepair region of the non-human DNA template that we 
have added to the original assay. The non-human DNA tem-
plate and its primer set act as an internal positive control (IPC) 5 
for successful DNA amplification. If the non-human DNA 
template is not amplified and a 200-nucleotide long amplicon 
is not visualized in the questioned DNA sample post-ampli-
fication, then chemical inhibitors are suspected to be present 
10 in the questioned sample. The sample can be further purified 
or diluted and re-quantified prior to attempting DNA profiling 
30 
(Whatmann, Incorporated, Florham Park, NJ) and graciously 
provided to us by the Tulsa Zoo and Living Museum in Tulsa, 
Okla. All other DNA samples used in this study were prepared 
from materials available to us in our laboratory. 
DNase I Digestions 
The NIST SRM Standard A male DNA sample was diluted 
to 1000 pg/µ!. Aliquots of this solution were combined with a 
volume of RNase-free DNase I (1 U/µl) (Promega Corp., 
Madison, Wis.) so that the final concentration ofDNase I was 
0.004 U/µl in a total volume of 157 µI. The final reaction mix 
was immediately aliquoted into nine separate tubes that were 
allowed to incubate for zero, one, two, three, four, five, fif-
teen, thirty, and sixty minutes. At the end of the incubation 
period, the appropriate amount of Stop Buffer (Promega 
Corp., Madison, Wis.) was added to each tube and the tube 
was heated at 65° C. for 10 minutes to halt enzyme activity. 1 
µI of these digests were amplified with the improved multi-
plex assay and analyzed by CEFD. 
EDTA Treatment 
on that sample. The non-human DNA template consists of the 
commercially available plasmid (the pRL-null vector from 
Promega Corporation, Madison, Wis.) from the marine 
15 
organism Renilla rentiformis ( a coelenterate known as the sea 
pansy). The plasmid, containing the 200 base pair amplicon 
that the additional primer set was designed to amplify, was 
selected because of its expected scarceness at crime scenes. 
Materials and Methods 
20 A volume of the NIST SRM Standard A male DNA sample 
was mixed with a volume of 0.5 M EDTA solution to make 
eleven mixtures containing 1000 pg/µL DNA in increasing 
final milli-molar amounts of EDTA per µL. The mixtures 
were constructed so that the addition of 1 µL to the improved 
DNA Extraction 
When necessary, DNA was extracted from sample material 
by one of two methods. One method employed a treatment 
with a solution containing 2% SDS, 20 µg/µL Proteinase K, 
10 mM Tris-Cl (pH 8.0), 1 mM EDTA, and 0.2 M NaCl. 
Samples were incubated in this solution at 56° C. for at least 25 
1 hour and then extracted with DNA-grade phenol:chloro-
form:isoamyl alcohol (25:24:1) (Sigma-Aldrich, St. Louis, 
Mo.). DNA was purified, concentrated, and de-salted using a 
Centricon device (Millipore Corporation, Billerica, Mass.). 
The other DNA extraction method employed the DNA IQ™ 30 
System with Differex™ or Tissue and Hair Extraction _Kit 
pre-treatment kits, as necessary (Promega Corporat10n, 
Madison, Wis.). Extracted and purified DNA was stored at 
-20° C. 
multiplex amplification reaction would give a final amplifi-
cationreaction volume of12.5 µL containing 1000 pg ofinput 
DNA in a final concentration of 0.0 mm EDTA, 0.1 mm 
EDTA, 0.2 mm EDTA, 0.3 mm EDTA, 0.4 mm EDTA, 0.5 
mm EDTA, 0.6 mm EDTA, 0.7 mm EDTA, 0.8 mm EDTA, 
0.9 mm EDTA, and 1.0 mm EDTA. 1 µL of these samples 
were amplified with the improved multiplex assay and ana-
lyzed by CEFD. 
Analyzed DNA Samples 
The NIST Standard Reference Material® (SRM) 2372 
Human DNA Quantitation Standard was utilized in this study. 
The NIST SRM 2372 Standard contains three standard 
samples (13). We utilized two of the standard samples to 
generate standard curves and verify the accuracy of the 
40 improved multiplex assay. The NIST SRM 23 72 Standard A 
PCR Amplification for the Improved Multiplex Assay 
Samples were amplified using an ABI 9700 thermal cycler 
(Applied Biosystems, Foster City, Calif.). The basi~ amplifi-
35 cation scheme for the original assay reported prev10usly (1) 
was optimized and dramatically shortened. The original the:-
mal cycling parameters were optimized using both theAmph-
Taq® Gold (Applied Biosystems, Foster City, Calif.) and 
is an all-male DNA sample containing 52.4 ng/µl DNA. The 
NIST SRM 2372 Standard Bis an all-female DNA sample 
containing 53.6 ng/µl DNA. In all instances in which a stan-
dard curve was generated, the DNA Standard solution was 
diluted in such a way as to generate a series of six DNA 45 
solutions containing 1000 pg/µ!, 500 pg/µ!, 250 pg/µ!, 125 
pg/µ!, 63 pg/µ!, and 32 pg/µ! of DNA material. All dilutions 
were prepared using sterile deionized H20 from a Millipore 
Elix and Milli-Q water system (Millipore Corporation, Bil-
lerica, Mass.). The QuantiB!ot® Standard A DNA, which is 50 
9947 A female DNA containing DNA at a concentration of 2 
ng/µl was purchased from Applied Biosystems (Foster City, 
Calif.) as part of a QuantiB!ot® Kit. This sample was utilized 
in this study as a pure female mock DNA evidence sample. A 
human NIST-traceable male DNA sample from our labora- 55 
tory was utilized in this study as a pure male mock _DNA 
evidence sample. This male DNA sample was extracted m our 
lab from a 1.5 mm punch of a bloodstained FTA® Card 
(Whatmann, Incorporated, Florham Park, N.J.) and then its 
2xGoTaq® Colorless Mastermix (Promega Corporation, 
Madison, Wis.) DNA polymerases. The optimized thermo-
cycling parameters for the improved multiplex assay consist 
ofa three-temperature cycle comprised often seconds at 98° 
C., sixty seconds at 55° C., and thirty seconds at 72° C. This 
three-temperature cycle is repeated 30 times, is followed by a 
ten-minute hold at 60° C., and then is followed by an infinite 
hold at room temperature (25° C.). These thermo-cycling 
parameters may be used interchangeably with either DNA 
polymerase listed above, but AmpliTaq® Gold requires an 
initial 11-minute hold at 96° C. to activate it. In our hands, the 
e2TAK DNA polymerase commercially available from 
TaKaRa Bio (Madison, Wis.) was not able to carry out opti-
mal amplification of the improved multiplex assay at the 
thermal cycling parameters described above. 
All primer sequences were synthesized by Invitrogen, 
Incorporated (Carlsbad, Calif.). The six primer sequences as 
ordered from Invitrogen included the three reverse primer 
sequences labeled with the blue fluorophore dye, FAM, and 
the three unlabeled forward primer sequences as follows: 
DNA concentration was quantified by the QuantiB!ot® (SEQ ID NO, 7) 
method as approximately 1 ng/µ1. In all instances in which a 60 AMEL forward - s' -Acc TCA TCC TGG GCA ccc TGG-3' 
standard dilution series of these pure samples was generated, 
the two DNA standard solutions were diluted in a series of 
halves as ½, ¼, 1/s, ½6, 1/32, and so on. All dilutions were AMEL reverse 
(SEQ ID NO, 8) 
5'-AGG CTT GAG GCC AAC CAT CAG-3' 
prepared using sterile deionized H20 from a Millipore Elix ( SEQ ID NO, 9) 
and Milli-Q water system (Millipore Corporation, Billerica, 65 SRY forward - 5' -ACG AAA GCC ACA CAC TCA AGA AT-3' 
Mass.). The non-human primate samples were prepared from 
liquid blood draws that were then spotted onto an FTA® Card 
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-continued 
(SEQ ID NO, 10) 
5'-CTA CAG CTT TGT CCA GTG GC-3' 
(SEQ ID NO, 11) 
5'-AAG GTG GTA AAC CTG ACG TTG-3' 
(SEQ ID NO, 12) 
5'-TTC ATC AGG TGC ATC TTC TTG-3' 
The primer sequences used to amplify the Amelogenin X 
and Y amplicons in the original assay were directly derived 
from publicly available sequence information used in the 
Promega Sex-Typing Kit (Promega Corporation, Madison, 
Wis.) (15). The primer sequences used to amplify the SRY 
amplicon in the improved multiplex assay were derived from 
the published sequence of the sex-determining region Y 
(SRY) gene (16) as well as published primer sequences used 
to amplify the SRY amplicon in other male-only human DNA 
quantification assays (11) (12). In the improved multiplex 
assay, the non-human DNA template material was added to 
each of the samples pre-amplification during the addition of 
the "master mix". The non-human DNA template material 
consists of the addition of the pRL null vector purchased from 
Promega Corporation (Madison, Wis.) that is diluted for use 
with sterile deionized H20 from a Millipore Elix and Milli-Q 
water system (Millipore Corporation, Billerica, Mass.). The 
optimal concentration of the primer sets, the pRL null vector, 
and the AmpliTaq® Gold (Applied Biosystems, Foster City, 
Calif.) within the master mix for amplification was previously 
optimized (18) for a reaction containing 12.5 µL final volume 
(11.5 µL master mix plus the addition of 1 µL questioned 
DNA sample) as 1.0 µM of Amelogenin primers, 1.0 µM of 
SRY primers, 0.1 µM of pRL primers, 0.5 pg of pRL plasmid. 
In this study, we opted to use the 2xGoTaq® Colorless Mas-
termix as our source of DNA Polymerase. The final optimal 
concentration of GoTaq® Colorless Mastermix was deter-
mined in this study to be 1.2x after addition of 7 .5 µL of 
2xGoTaq® Colorless Mastermix to the 12.5 µL total reaction 
volume. 
Genetic Analysis of Samples Amplified by the Improved 
Multiplex Assay 
The products of amplification resulting from the improved 
multiplex assay were analyzed using an ABI Prism 310 
Genetic Analyzer (Applied Biosystems, Foster City, Calif.). 
1.5 µL of amplified sample was mixed with 24.5 µL HiDi 
formamide (Applied Biosystems, Foster City, Calif.) and 0.5 
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in our laboratory for describing and characterizing the four 
potential products of amplification resulting from the 
improved multiplex assay. 
Generation of Standard Curves and Data Analysis for the 
5 Improved Multiplex Assay 
A standard curve for the improved multiplex assay was 
created by plotting the pre-amplification amount of DNA 
within a NIST SRM 2372 Standard A or B sample dilution 
series as described above against the peak-height RFU gath-
10 ered for each sample in the dilution series with CEFD. For 
estimation of the DNA concentrations in unknowns, the peak 
height RFU value for each amplicon was compared against 
the standard curve data to determine a corresponding pico-
gram amount of DNA for a peak of that RFU. To determine 
15 the total human DNA content within an unknown tube, the 
Amelogenin X and/or Y amplicon's peak-height RFU was 
compared to a female Amelogenin X standard curve to deter-
mine picogram amounts. To determine the amount of male 
DNA within an unknown sample, the SRY amplicon's peak 
20 height RFU in comparison to a male SRY standard curve 
determined the pico gram amount in that sample. The percent 
coefficient of variation (CV) for a run of samples via CEFD 
was determined by running the 250 pg/µL NIST SRM 2372 
Standard B female three times during any run, to sum the 
25 peak-height RFU for the Amelogenin X amplicon, and deter-
mine the mean, standard deviation, and percent CV for those 
three runs to determine the percent CV for electrophoretic 
injection for the CEFD instrument during the run. The same 
250 pg/µL NIST SRM 2372 Standard B female sample was 
30 compared to the female Amelogenin X standard curve to 
ensure that the picogram amount estimated to be within that 
sample never exceeded a total CV of thirty percent (inclusive 
of the percent CV of the CEFD instrument used in the run). 
DNA Quantification Using QuantiB!ot®, Quantifiler®, and 
35 Quantifiler® Y 
Estimates of DNA concentration in crime scene samples 
were produced using blotting/hybridization methods incor-
porated into the QuantiB!ot® kit using colorimetric detection 
(Applied Biosystems, Foster City, Calif.). The highest con-
40 centration of quantity made by this method was estimated as 
8 ng/µL ( a two-fold intensity increase from the 2 ng/µL Quan-
tiB!ot® Standard A DNA sample supplied with the Quan-
tiB!ot® kit). The lowest concentration of quantity made by 
this method was estimated as ~0.125 ng/µl (the fourth dilu-
45 tion in a two-fold dilution series of the 2 ng/µL QuantiB!ot® 
Standard A DNA sample supplied with the QuantiBlot® kit). 
No attempt was made to estimate DNA sample concentration 
below 0.125 ng/µL as any sample exhibiting less than this 
amount would require amplification of the full 10 µL allow-µL GS-500 LIZ size standard (Applied Biosystems, Foster 
City, Calif.) according to recommendations of the supplier. 
Prepared samples were then electrokinetically injected for 
five seconds, four seconds, three seconds, two seconds, or one 
second depending upon the particular instrument utilized and 
the nature of the experiment performed. After injection, 
samples were allowed to electrophoresis for 21 minutes. 
Relative fluorescence unit (RFU) data (peak-height) was col-
lected using the Macintosh-based 310 Collection Software 
with 5-dye collection. The original assay used a 4-dye plat-
form for the detection of the FAM-labeled amplicons (1). We 
could distinguish no change in the detection of FAM-labeled 60 
amplicons using a 5-dye platform. In both platforms, the size 
standard is a dye having no spectral overlap with FAM. The 
GeneScan® Analysis version 3 .1.2 software program was set 
50 able for later DNA profiling with the AmpFlSTR® Identi-
filer™ and/or the AmpFlSTR® Yfiler™ PCR Amplification 
Kits (Applied Biosystems, Inc, Foster City, Calif.). Actual 
casework DNA samples were also quantified by Sorenson 
Forensics, Inc. (Salt Lake City, Utah) using the Quantifiler® 
55 kit and the Quantifiler® Y kit from Applied Biosystems, Inc. 
(Foster City, Calif.) with all quantification data graciously 
provided to us after their analyses. 
PCR Amplification and Genetic Analysis for Generating 
DNA Profiles 
Some samples of purified and quantified DNA were diluted 
so that approximately 1 ng of DNA from the sample was 
targeted for amplification using an ABI 9700 thermal cycler 
(Applied Biosystems, Foster City, Calif.) in a 25-µL reaction 
volume using theAmpFlSTR® Identifiler™ PCRAmplifica-
tion Kit and/or theAmpFlSTR® Yfiler™ PCRAmplification 
Kit (Applied Biosystems, Inc, Foster City, Calif.) according 
to the manufacturer's default settings with a peak amplitude 
threshold set at 50 relative fluorescence units (RFU s ). Alleles 65 
were then size-called and labeled with peak-height RFU 
using a Genotyper® version 2.5.2 software macro developed to manufacturer's specifications. Products of amplification 
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were analyzed using an ABI Prism 310 Genetic Analyzer 
(Applied Biosystems, Foster City, Calif.). 1.5 µL of amplified 
sample was mixed with 24.5 µL HiDi formamide (Applied 
Biosystems, Foster City, Calif.) and 0.5 µL GS-500 LIZ size 
standard (Applied Biosystems, Foster City, Calif.) according 5 
to recommendations of the supplier. Prepared samples were 
then electrokinetically injected for five seconds and allowed 
to electrophoresis for 28 minutes using a five-dye platform. 
Data was collected using the Macintosh-based 310 Collection 
Software with 5-dye collection, analyzed with the GeneS- 10 
can® Analysis version 3.1.2 software, and then size-called 
and labeled using the manufacturer-supplied macros for the 
Genotyper® version 2.5.2 software. 
Results 
The original assay and the improved multiplex assay both 15 
function on several theoretical premises. The first is that the 
amount of DNA residing in a sample pre-amplification will 
amplify with the same kinetics of amplification dependent 
upon the amount of input DNA and that the amplification 
kinetics of a basic polymerase chain reaction (PCR) will 20 
result in a reproducible amount of end-point amplification 
product. The second premise is that the end-point products of 
amplification can be analyzed by CEFD and that during 
CEFD analysis, a certain amount of the product will be repro-
ducibly diluted for introduction into the CEFD device, this 25 
diluted product will be reproducibly electrokinetically 
injected into the capillary of the CEFD device, and the DNA 
product as it passes the detection mechanism will emit a 
reproducible amount of fluorescence. This fluorescence will 
34 
gathered from the Amelogenin X amplicon for every dilution 
in the series results in a standard curve that can be seen in FIG. 
7b. We expected that the data points would represent a one to 
one relationship between the amount of fluorescence and the 
amount of input DNA pre-amplification. In other words, we 
expected an R 2 value of 1.0 and we expected that the line of 
regression (seen as a bold line) in FIG. 7 should mirror the 
plotted line of the average of the fluorescence data gathered at 
each dilution ( dotted line). But as one can see, the relationship 
did not appear to be linear based upon the data plotted in FIG. 
7 or in the previously published original assay (1). We then 
determined that our data was probably being skewed because 
the dynamic range of the assay was out of the linear range for 
the CEFD device. We determined from the raw CEFD data 
that the peak height RFU estimates were truncated for the 
1000 pg DNA samples. Truncation of peaks would indicate 
that the limit of linearity (LOL) for the CEFD device was 
being exceeded. We also decided to not use sample dilutions 
ofless than 63 pg to generate our standard curves because the 
limit of quantification (LOQ) for the CEFD device we were 
using was anywhere from 35 pg to 100 pg (19, 20). The 
standard curve that resulted from plotting a dilution series 
ranging from 63 pg/µL to 500pg/µL for the NIST SRM 2372 
StandardAmale and the NIST SRM2372 StandardB female 
versus the average fluorescence (peak height RFU) that is 
gathered from the appropriate amplicon for every dilution in 
the series results in the standard curves that can be seen in the 
male SRY standard curve in FIG. Sa and the female Amelo-
genin X standard curve in FIG. Sb. After accounting for the 
linear and dynamic range of the CEFD device, a valid linear 
relationship between the male SRY standard curve was exhib-
ited with an R2 value of0.9984 in FIG. Sa and a valid linear 
relationship between the female X standard curve was exhib-
ited with an R2 value of0.9980 in FIG. Sb. We then evaluated 
the accuracy of the improved multiplex assay standard curves 
to determine the amount of total human and male-only DNA 
residing in samples of known concentration. In FIG. 6a, the 
female X standard curve was used to determine the total 
be reproducibly collected by the CEFD device. If these pre- 30 
mises hold true, then the fluorescence of the amplification 
product of a DNA sample will be directly proportional to the 
amount of DNA residing in a sample pre-amplification. The 
incidence of fluorescence for a dilution series of DNA 
samples of varying DNA content can be plotted as a standard 35 
curve and the standard curve can be used to determine the 
amount of input DNA that must have resided in any unknown 
sample pre-amplification by knowing its level of fluorescence 
during CEFD analysis. However, over ten separate amplifi-
cations a standard curve generated from the original assay had 
a reported R 2 value of0.97 51 and a CV ofabout thirty percent 
(1). The source of the CV was not characterized or under-
stood. If a dilution series ranging from 32 pg/µL to 1000 
pg/µL of the NIST SRM 2372 Standard A male is amplified 
using the improved multiplex assay and run on a CEFD 45 
device the average fluorescence (peak height RFU) that is 
gathered from the SRY amplicon for every dilution in the 
series results in a standard curve that can be seen in FIG. 7a. 
Similarly, if a dilution series ranging from 32 pg/µL to 1000 
pg/µL of the NIST SRM 2372 Standard B female is amplified 50 
using the improved multiplex assay and run on a CEFD 
device the average fluorescence (peak height RFU) that is 
human DNA content of a dilution series of known DNA made 
40 from the NIST SRM 2372 Standard A male. In FIG. 6b, the 
female X standard curve was used to determine the total 
human DNA content of a dilution series of known DNA made 
from the NIST SRM 2372 Standard B female. In FIG. 6c the 
male SRY standard curve was used to determine the male-
only DNA content of a dilution series of known DNA made 
from the NIST SRM 23 72 Standard A male. FIG. 6a exhibited 
an R2 value of 0.9992, FIG. 6b exhibited an R2 value of 
0.9985, and FIG. 6c exhibited an R2 value of0.9979 demon-
strating that the improved multiplex assay functions with a 
very high degree of accuracy. In Table 5 the percent CV was 
examined for the data sets used to generate the three FIG. 6 
graphs. 
TABLES 
Reproducibility of the Improved Multiplex Assay 
# Sample Run! Run2 Run3 µ (J CV 
1 NIST A 1000 pg Amel (X + Y) RFU 13612 12321 12470 12801 706.3 5.52% 
IMA total human estimated pg of DNA 950 859 870 893 49.67 5.56% 
2 NIST A 500 pg Amel (X + Y) RFU 9198 6716 6765 7559.67 1419 18.77% 
IMA total human estimated pg of DNA 639 464 468 523.667 99.9 19.08% 
3 NIST A 250 pg Amel (X + Y) RFU 3869 3524 4777 4056.67 647.2 15.95% 
IMA total human estimated pg of DNA 264 240 328 277.333 45.49 16.40% 
4 NIST A 125 pg Amel (X + Y) RFU 2572 1888 2142 2200.67 345.8 15.71% 
IMA total human estimated pg of DNA 172 124 142 146 24.25 16.61% 
5 NIST A 63 pg Amel (X + Y) RFU 1572 1073 872 1172.33 360.4 30.74% 
IMA total human estimated pg of DNA 102 67 53 74 25.24 34.11 % 
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TABLE 5-continued 
Re12roducibili!Y of the Im12roved Multi12lex Assay 
# Sample Run 1 Run2 Run3 µ (J CV 
6 NIST A 32 pg Amel (X + Y) RFU 635 483 535 551 77.25 14.02% 
IMA total human estimated pg of DNA 36 25 29 30 5.568 18.56% 
Average a of Total Human RFU for# 1-6 592.7 16.79% 
Average a of Total Human DNA (pg) for# 1-6 41.69 18.39% 
Average a of Total Human RFU for# 2-5 693.1 20.30% 
Average a of Total Human DNA (pg) for# 2-5 48.72 21.55% 
R2 value ofpg for# 1-6 0.9719 0.9980 0.9822 0.9914 0.013 1.33% 
R2 value of pg for# 2-5 0.9810 0.9999 0.9394 0.9992 0.031 3.10% 
1 NIST B 1000 pg Amel (X + Y) RFU 7385 7450 6270 7035.00 663.31 9.43% 
IMA total human estimated pg of DNA 511 516 433 486.67 46.54 9.56% 
2 NIST B 500 pg Amel (X + Y) RFU 7532 7376 6624 7177.33 485.51 6.76% 
IMA total human estimated pg of DNA 522 511 458 497.00 34.22 6.89% 
3 NIST B 250 pg Amel (X + Y) RFU 3629 3428 4175 3744.00 386.55 10.32% 
IMA total human estimated pg of DNA 247 233 285 255.00 26.91 10.55% 
4 NIST B 125 pg Amel (X + Y) RFU 1729 2373 1910 2004.00 332.13 16.57% 
IMA total human estimated pg of DNA 113 158 126 132.33 23.16 17.50% 
5 NIST B 63 pg Amel (X + Y) RFU 699 986 971 885.33 161.54 18.25% 
IMA total human estimated pg of DNA 41 61 60 54.00 11.27 20.87% 
6 NIST B 32 pg Amel (X + Y) RFU 376 667 423 488.67 156.22 31.97% 
IMA total human estimated pg of DNA 18 38 21 25.67 10.79 42.02% 
Average a of Total Human RFU for# 1-6 364.21 15.55% 
Average a of Total Human DNA (pg) for# 1-6 25.48 17.90% 
Average a of Total Human RFU for# 2-5 341.43 12.98% 
Average a of Total Human DNA (pg) for# 2-5 23.89 13.95% 
R2 value ofpg for# 1-6 0.7912 0.8112 0.7270 0.7837 0.04 5.61% 
R2 value of pg for# 2-5 0.9999 0.9880 0.9784 0.9985 0.01 1.08% 
1 NIST A 1000 pg SRY RFU 7602 7577 7283 7487.33 177.40 2.37% 
IMA total male estimated pg of DNA 655 652 627 644.67 15.37 2.38% 
2 NIST A 500 pg SRY RFU 6066 5629 5623 5772.67 254.05 4.40% 
IMA total male estimated pg of DNA 522 484 484 496.67 21.94 4.42% 
3 NIST A 250 pg SRY RFU 3659 2156 3062 2959.00 756.78 25.58% 
IMA total male estimated pg of DNA 315 185 263 254.33 65.43 25.73% 
4 NIST A 125 pg SRY RFU 1366 1421 1921 1569.33 305.79 19.49% 
IMA total male estimated pg of DNA 117 122 165 134.67 26.39 19.60% 
5 NIST A 63 pg SRY RFU 578 968 313 619.67 329.48 53.17% 
IMA total male estimated pg of DNA 49 83 26 52.67 28.68 54.45% 
6 NIST A 32 pg SRY RFU 456 267 456 393.00 109.12 27.77% 
IMA total male estimated pg of DNA 38 22 38 32.67 9.24 28.28% 
Average a Male-Only RFU for# 1-6 322.10 22.13% 
Average a Male-Only DNA (pg) for# 1-6 27.84 22.48% 
Average a Male-Only RFU for# 2-5 411.53 25.66% 
Average a Male-Only DNA (pg) for# 2-5 35.61 26.05% 
R2 value ofpg for# 1-6 0.8973 0.9456 0.9133 0.9288 0.025 2.65% 
R2 value of pg for# 2-5 0.9780 0.9673 0.9699 0.9979 0.006 0.56% 
For Table 5, the percent CV was calculated for each pico-
45 gram amount of input DNA ranging from 32 pg/µL to 1000 
pg/µL for each standard curve analysis in FIG. 6. The percent 
CV was also calculated for each total fluorescence value of 
the relevant amplicons observed to calculate either total 
Table 5 shows NIST SRM 2372 Standard A and B at the 
concentrations produced by the serial dilution scheme 
described in the Materials and Methods. Three separate 
amplifications were performed for each concentration of 
Standard A and Standard Band injected for five seconds on an 
ABI Pri= 310 Genetic Analyzer. The mean RFU height, 
standard deviation, and coefficient of variation were calcu- 50 
lated for the sum of the Amelogenin X and Amelogenin Y 
amplicons and for the SRY amplicon from the three separate 
amplifications. The average RFU height of the sum of the 
Amelogenin X and Amelogenin Y amplicons after the three 
amplifications was used to construct a standard curve to pro- 55 
duce the total human DNA estimate within each dilution. The 
average RFU height of the SRY amplicon after the three 
amplifications was used to construct a standard curve to pro-
duce the male-only DNA estimate within each dilution. The 
average standard deviation and coefficient of variation for 
each dilution was calculated for the RFU height of the rel-
evant amplicon(s) and estimated amount of DNA for the 32 
pg/µL-1000 pg/µL range of data as well as for the 63 pg/µL-
500 pg/µL range of data. The R 2 value for each amplification 
and for the average of the three amplifications for the amount 
of DNA was calculated, along with the standard deviation and 
coefficient of variation. 
human (sum of fluorescence from the Amelogenin X and 
Amelogenin Y amplicons) or male-only (fluorescence ofSRY 
amplicon) DNA concentration for each amount of input DNA 
ranging from 32 pg/µL to 1000 pg/µL. When calculating the 
amount of total human DNA in the NIST SRM 23 72 Standard 
A male DNA ranging from 32 pg/µL to 1000 pg/µL the 
average percent CV is 16.79% for RFU, 18.39%forpicogram 
amount of DNA. If graphed, the linear relationship of these 
points has an average R2 value of 0.9914. For this same 
sample, if the range of DNA concentrations narrows from 63 
pg/µL to 500 pg/µL the average percent CV is 20.30% for 
60 RFU, 21.55% for picogram amount of DNA. If graphed, the 
linear relationship of these points has an average R2 value of 
0.9992. When calculating the amount of total human DNA in 
the NIST SRM 2372 Standard B female DNA ranging from 
32 pg/µL to 1000 pg/µL the average percent CV is 15.55% for 
65 RFU, 17.90% for picogram amount of DNA and the linear 
relationship of these points has an average R 2 value of0.783 7. 
This same sample with a narrowed range demonstrate an 
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average percent CV is 12.98% for RFU, 13 .95% for picogram 
amount of DNA, and an average R2 value of 0.9985. When 
calculating the amount of male-only DNA in the NIST SRM 
2372 Standard A male DNA ranging from 32 pg/µL to 1000 
pg/µL the average percent CV is 22.13% for RFU, 22.48% for 5 
picogram amount of DNA. If graphed, the linear relationship 
of these points has an average R2 value of0.9288. This same 
sample with a collapsed range has an average percent CV of 
25.66% for RFU, 26.05% forpicogram amount of DNA, and 
an average R2 value of0.9979. We decided from this data that 10 
the standard curves for the improved multiplex assay should 
be generated from the 63 pg/µL, 125 pg/µL, 250 pg/µL, and 
the 500 pg/µL dilutions of standard DNA reference material 
as these samples generated better R2 values. 
Data concerning the reproducibility of the improved mu!- 15 
tiplex assay and the ability to estimate the picogram amount 
of input DNA in a male and a female sample at various 
dilutions of that sample with an improved multiplex assay 
standard curve, is presented in FIG. 14 in tabular form. 
For FIG. 14, the concentration of DNA within the samples 20 
was not precisely known (see the Materials and Methods 
section for information concerning general concentration of 
these samples) so these samples were serial diluted by halves 
and subjected to amplification and analysis using the 
improved multiplex assay. The percent CV was calculated for 25 
estimated pico gram amounts of DNA in 1 µL of each serial 
dilution and the fluorescence amounts of the relevant ampli-
cons for each serial dilution of the male sample and female 
sample as indicated in FIG. 14. When calculating the amount 
38 
eighteen analyses of this single sample by each device, we 
determined the percent CV of a CEFD device for size-calling 
and for electrokinetic injection and fluorescence detection of 
a sample. The results are presented in tabular form in FIG.15. 
Our conclusion was that the percent CV for any particular 
CEFD device can be kept below 5% with proper attention to 
instrument set-up and maintenance. To determine the instru-
mental percent CV for every standard curve and sample run 
performed in this study, we chose to serially inject the NIST 
SRM 23 72 Standard B female 250 pg/µL dilution three times, 
once near the beginning of a run, once in the middle of a run, 
and once near the end of a run. The average peak height 
fluorescence of the Amelogenin X amplicon in this sample 
would be used to determine the CEFD percent CV for all 
sample data gathered during that run. The highest CEFD CV 
noted for any of the sample runs used to generate the 
improved multiplex assay data presented in this study was 
5.68% with the average CEFD CV being 3.33% over all runs 
(data not shown). 
PCR was the only remaining component for the introduc-
tion of variation to the improved multiplex assay. Stochastic 
effects were expected to cause a certain amount of variation of 
amplified product to arise from a specific amount of input 
DNA. Due to these stochastic effects, the limit of detection for 
the PCR reaction has already been documented for qualitative 
DNA analysis (DNA profiling based upon a qualitative 
assessment of amplicon appearance or drop-out after size-
migration through a CEFD device) at around 35 pg of total 
input DNA (20, 21 ), but what would be the percent CV for the 
PCR reaction itself? Ifwe look back to the data presented in 
Table 5, the percent CV for each pico gram amount of input 
DNA is given and the average, as stated previously is approxi-
mately 20% (range of 13% to 26%). If pipetting and dilution 
CV is approximately 1 % and CEFD detection is approxi-
of total human DNA in all dilutions of the female sample, the 30 
average percent CV is 23.77% for RFU, and 21.03% for 
picogram amount of DNA (FIG. 14). When calculating the 
amount of total human DNA in all dilutions of the male 
sample, the average percent CV is 23.16% for RFU, and 
21.36% for picogram amount of DNA (FIG. 14). When cal-
culating the amount of male-only DNA in all dilutions of the 
male sample, the average percent CV is 21.06% for RFU, and 
20.49% for picogram amount of DNA (FIG. 14). 
35 mately 5%, then approximately 14% CV remains with a range 
of remaining CV of 7% to 20%. We theorize that the PCR 
reaction itself has a CV of 10-15% when the input DNA is 
between 63 pg and 500 pg. The data generated by our 
improved multiplex assay also indicates that the PCR CV The CV for the improved multiplex assay as a whole was 
approximately 20% from the accuracy data presented in Table 40 increases beyond 10-15% when the input DNA is below 63 
pg. An increased CV for input DNA below 63 pg is also seen 
in other PCR-based quantification methods, namely the 
Quantifiler® and Quantilfer® Y kits (10). The effect of intro-
ducing more than 500 pg of input DNA into the PCR reaction 
5 with a range of 13% to 26%. We next wanted to determine 
the percent CV contributed by each component of the 
improved multiplex assay. Several opportunities exist in the 
improved multiplex assay for introducing variation into the 
estimation of DNA quantity in a sample. We theorized that the 
potential existed for the introduction of variance during 
sample pipetting ( during the creation of a dilution series or the 
dilution of amplified sample for CEFD analysis), during the 
PCR amplification step (stochastic effects), during the elec-
trokinetic injection of a sample into the CEFD device, and 
during the detection and collection of peak height data by the 
CEFD device. The twenty pipetting devices utilized in our 
laboratory are calibrated in triplicate every year. These 
devices have an average documented CV of 0.16%. Even 
considering the additive pipetting error seen in the creation of 
serial dilutions, pipetting percent CV seemed to be no greater 
than 1 % in our laboratory. This left 19% of the 20% average 
CV seen in the improved multiplex assay unaccounted for. 
Next, we determined the percent CV introduced during elec-
trokinetic injection and fluorescent detection on five CEFD 60 
devices. To determine the percent CV for a CEFD device, we 
serially injected (eighteen times in a row) one sample of the 
amplification products from an AmpFISTR® Identifiler™ 
DNA profiling reaction performed on the Indentifiler™ 
female positive control on five CEFD devices. By determin- 65 
ing the average peak-height fluorescence and size-calling 
data of the TH0l 9 .3 allele exhibited by this sample during the 
45 is unknown for the improved multiplex assay because of the 
limit oflinearity of the CEFD device. 
During our study we noted that some CEFD devices are 
more sensitive in detecting fluorescence than others. 
Increased sensitivity translates to a lowered LOL for a CEFD 
50 device. An input DNA of <500 pg will appear truncated if a 
CEFD device with a lowered LOL is used for analysis. In this 
instance, we developmentally validated using electrokinetic 
injection times of less than five seconds on CEFD devices 
with an increased sensitivity. The results of a shortened elec-
55 trokinetic injection time on a sensitive CEFD device are pre-
sented in FIG. 7. In FIG. 7a the effects of increased CEFD 
sensitivity on the generation of a standard curve from 63 pg, 
125 pg, 250 pg, and 500 pg input standard DNA reference 
material is shown. The result of increased sensitivity on this 
CEFD device is to gather truncated peak height RFU data. 
Truncation makes the peak height RFU value invalid. FIGS. 
7b, 7c, 7d, and 7e show the standard curves generated from 
the same input DNA amounts with decreasing electrokinetic 
injection times of 4, 3, 2, and 1 second, respectively. Based 
upon the information presented in FIGS. 4-7, Tables 5, and 
FIGS. 14 and 15, we determined how best to evaluate the 
quality of an improved multiplex assay standard curve. We 
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determined that a good standard curve must have an R 2 value 
of >0.98 and that the limit of detection for the PCR reaction 
should be used as another means of assessment. As discussed 
earlier, the limit of detection for the PCR reaction is already 
well documented for qualitative DNA analysis at around 35 5 
pg of total input DNA which corresponds to an average CEFD 
peak height RFU of 150 (20, 21 ). To use this value for assess-
ing the quality of a standard curve, the RFU value of 150 is 
plugged into the standard curve. The picogram amount plus 
thirty percent (the upper bound picogram amount if the per- 10 
cent CV equals 30% at an RFU of 150 should be calculated by 
the standard curve as an input DNA of less than 35 pg. The 
limit of detection (LOD) for the CEFD device defaults at 50 
RFU. Ifa value of 50 RFU is entered into a standard curve, the 15 
pico gram amount given should also correspond to the amount 
of DNA within a "blank" sample, since 50 RFU is the default 
LOD for a CEFD device. Using these assessments, the best 
standard curve data generated in FIG. 7 would be the standard 
curves generated from the 2- and 3-second electrokinetic 20 
injection times for that CEFD device. 
With the ability to evaluate the quality of an improved 
multiplex assay standard curve, we began to examine the 
specificity and sensitivity of the improved multiplex assay 
based upon the appearance of the four possible amplicons in 25 
the assay (see FIG. 8). When amplicons were apparent, the 
peak height RFU for the relevant amplicons were compared 
to the femaleAmelogeninX amplicon-derived standard curve 
(to determine total human DNA quantity in a sample) or the 
male SRY amplicon-derived standard curve (to determine 30 
male-only DNA quantity in a sample) (standard curves are 
presented in FIGS. Sa and Sb). The original assay utilized 
only one primer set to evaluate the diploidAmelogenin ampli-
cons (X and Y). We wanted to determine the effect of a 35 
multiplex of primer sets on the ability to analyze the peak 
height RFU of each amplicon. To do this, we amplified 250 pg 
of the NIST SRM 2372 Standard B female, the NIST SRM 
Sample Arnplicon 
40 
TABLE6A 
Peak height RFU data 
Relative Flourescence Units in Height 
Arnplicons SRY pRL 
NIST SRM 2372 B (250 pg) 
pRL 0 5368 
Arnelogenin 0 0 
SRY 0 0 
SRY +pRL 0 7377 
pRL + Arnelogenin 0 6960 
SRY + Arnelogenin 0 0 
Tri-Plex 0 8000 
NIST SRM 2372 A (250 pg) 
pRL 0 5031 
Arnelogenin 0 0 
SRY 3347 0 
SRY +pRL 2863 7491 
pRL + Arnelogenin 0 7484 
SRY + Arnelogenin 4555 0 
Tri-Plex 4321 7368 
Water 
pRL 0 5769 
Arnelogenin 0 0 
SRY 0 0 
SRY +pRL 0 6820 
pRL + Arnelogenin 0 7670 
SRY + Arnelogenin 0 0 
Tri-Plex 0 7505 
TABLE6B 
Average singleplex, duplex, and triplex RFU values 
Singleplex 
RFU 
Relative Fluorescence 
Units 
Duplex Avg. 
RFU Triplex RFU µ 
X y 
0 0 
5241 0 
0 0 
0 0 
4683 0 
5535 0 
4366 0 
0 0 
2346 2860 
0 0 
0 0 
2947 1553 
2118 2540 
2278 2697 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
(J CV 
NIST A Arnelogenin X 5241 5109 4366 4905 471.72 9.62% 
5.54% 
16.97% 
6.43% 
12.98% 
NISTB Arnelogenin X 2346 2533 2278 2386 132.05 
Arnelogenin Y 2860 2047 2697 2535 430.12 
Arnelogenin X + Y 5206 4580 4975 4920 316.56 
SRY 
2372 Standard A male, and a blank (sterile deionized H20). 
The improved multiplex assay amplifies differing amplicons 
depending upon the gender of the amplified sample (FIG. 8). 
In all cases, the internal positive control (IPC) template DNA 
(pRL null vector) was added to each sample. Table 6A pre-
sents the peak height RFU data gathered for the male, female, 
and blank DNA samples using each possible primer single-
plex, primer duplex, or primer triplex (improved multiplex 
assay) as indicated. Table 6B presents the average singleplex, 
duplex, and triplex RFU values obtained for each amplicon 
except the IPC. The CV column of Table 6B indicates that all 
peak height variation among each reaction varied no more 
than 16.97% for any amplicon, no matter which reaction was 
carried out. 
3347 3709 4321 3792 492.32 
The non-human primate specificity of the Amelogenin 
55 primer set (17) and the non-human primate specificity of the 
original assay (Example 1) and (1) has been previously dem-
onstrated. The SRY primer set used in the improved multiplex 
assay amplifies a region on the SRY gene that has demon-
strated high levels of human-specificity when used in other 
PCR reactions (22). The human-specificity of the improved 
60 multiplex assay as compared to three types of non-human 
primates is presented in FIG. 9. The Amelogenin X amplicon 
is produced with varying efficiencies among the five non-
human primates tested. The male non-human primate sample 
did not exhibitAmelogenin Y amplicon production, nor did it 
65 exhibit SRY amplicon production. 
The original assay could not detect the presence of PCR 
inhibitors. With the addition of the IPC (the pRL plasmid and 
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its corresponding primer set) the improved multiplex assay 
can very sensitively indicate inhibition with many known 
inhibitors of PCR (18). FIG. lOa demonstrates the decreasing 
amounts of peak-height RFU obtained in a male DNA sample 
treated with increasing amounts of EDTA, a known PCR 5 
amplification inhibitor. In FIG. 10b the ratio oftheAmeloge-
nin X, Amelogenin Y, and SRY amplicon peak height RFU to 
the peak height RFU of the IPC is shown. At a final concen-
tration of0.8 mM EDTA in the PCRreaction, the IPC begins 
to exhibit much less peak height RFU in relation to the other 10 
amplicons. At the 0.9 mM EDTA final concentration, the IPC 
has vanished. The IPC of the improved multiplex assay 
appears to be more sensitive to inhibition than the other 
amplicons, which would allow inhibition to be detected by 15 
the IPC in this assay before the effects were as apparent in the 
other amplicons. 
42 
values that would be expected from these DNA samples post-
amplification if the estimated input DNA value was indeed 
accurate. 
TABLE 7 
Dilution scheme for Yfiler profiling based on quantification 
values estimated by IMA for 12 samples 
Sample 
1 to 1 (whole blood) 
5 to 1 (whole blood) 
10 to 1 (whole blood) 
IMA 
Estimate 
of Male 
DNA in 
1 uL 
1850 
337 
179 
Dilution 
Recipe in TE 
in 17 
4 in 9 
12 in 9 
pgof 
Average 
RFU 
of the seven 
European 
Minimal 
Haplotype 
DNA in from Y Filer 
l0uL profiling 
1028 5073 
1037 4981 
1023 5611 
The addition of the SRY amplicon to the multiplex assay 
allowed for an increase in the ability of this assay to detect the 
presence of male DNA far beyond the ability of the original 20 
assay. Two studies were done to determine the ability of the 
SRY amplicon and theAmelogenin Y amplicon to detect male 
DNA in a preponderance of female DNA. FIG. lla shows the 
results obtained when exact ratios of the NIST SRM 2372 
Standard A male DNA was mixed with increasing amounts of 
NIST SRM 23 72 Standard B female DNA. Each solution was 
created so that the concentration of the male DNA was a 
constant 125 pg/µL while admixed female DNA increased at 
the ratios to the male DNA as shown. In these pure DNA 
liquid mixtures, the Amelogenin Y amplicon was not able to 
25 20 to 1 (whole blood) 61 610 4139 
50 to 1 (whole blood) 
100 to 1 (whole blood) 
500 to 1 (whole blood) 
53 
20 
0 
530 3483 
200 1081 
193 
be detected in the 1 :20 ratio or greater. Note that a 1 :20 ratio 30 
1000 to 1 0 154 
of male to female DNA is a ratio of 1:41 fortheAmelogenin 
Y amplicons to the Amelogenin X amplicons and a ratio of 1 
to nothing for the SRY amplicons. In FIG. llb the same 
experiment was carried out, but the mixtures were created by 
mixing ratios of male and female whole human blood, drying 
this blood, and then extracting the DNA from a consistent 
sample size of the blood mixtures. In this experiment, the 
Amelogenin Y amplicon was not able to be detected in the 
1 :50 ratio or greater. This experiment indicates the increased 
sensitivity of the SRY amplicon to detect male DNA in mixed 
samples. 
35 
40 
But how do these ratios translate into the ability to success-
fully profile the Y chromosomal haplotype using the Yfiler™ 
PCRAmplification Kit? Table 7 demonstrates the YSTR pro-
filing results obtained using the improved multiplex assay's 45 quantification estimate of the male-only DNA content of 
these mixed samples to target the amount ofinput DNA (1000 
pg) for successful YSTR profiling results according to the 
manufacturer (23). The average peak height RFU observed 
for the six minimal European haplotypes reflect the RFU 
(whole blood) 
1 to 1 (DNA solution) 
1 to 50 
(DNA solution) 
1 to 100 
(DNA solution) 
1 to 400 
(DNA solution) 
97 
53 
112 
92 
970 5840 
530 5522 
10 in 1018 1441 
920 2501 
The ability of the original assay to provide accurate quan-
tification of total human DNA in forensic samples was con-
firmed (1 ). In this study, the concentration of DNA in eleven 
actual casework samples was evaluated by the improved mul-
tiplex assay by comparing the quantification values deter-
mined by theAmelogeninX and/or Amelogenin Y amplicons 
to the quantification values determined during Quantifiler® 
analysis (see Table 8). 
TABLES 
Dilution scheme for Yfiler profiling based on quantification 
values estimated by IMA for 11 actual cases 
IMA Quantifiler Mean(µ) 
Estimate Estimate Estimate 
of Total of Total of Total pg of Most 
Sample Human Human Human Dilution DNAin Accurate 
Number DNA DNA DNA Recipe in TE l0uL Identifiler EP Estimate 
3725 4409 4067 in 39 1017 over-amplified Quantifiler 
2 451 1103 777 2 in 13 1036 over-amplified Quantifiler 
3 3650 2616 3133 in 30 1011 slightly over- IMA 
amplified 
4 6 1396 701 2 in 12 1001 under-amplified IMA 
5 531 606 568.5 2 in 9 1034 slightly over- Quantifiler 
amplified 
6 13075 10400 11737.5 in 116 1003 over-amplified IMA 
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TABLE 8-continued 
Dilution scheme for Yfiler profiling based on quantification 
values estimated by IMA for 11 actual cases 
Quantifiler Mean(µ) 
Estimate Estimate 
of Total of Total pg of 
Human Human Dilution DNAin 
44 
Most 
Accurate 
Number DNA DNA DNA Recipe in TE l0uL Identifiler EP Estimate 
7 80 734 407 4 in 12 1018 under-amplified IMA 
8 1425 864 1144.5 2 in 20 1040 over-amplified IMA 
9 990 1046 1018 in 9 1018 over-amplified Quantifiler 
10 750 757 753.5 2 in 13 1005 under-amplified IMA 
11 976 1041 1008.5 in 9 1009 slightly over- Quantifiler 
amplified 
In order to make this comparison, the total human DNA 
concentration quantification results for both methods were 
averaged together. This average quantification value was used 
In order to make this comparison, the male-only DNA 
quantification results for both methods were averaged 
together. This average quantification value was used to cal-
20 culate the amount of DNA sample to add to a Yfiler™ (Ap-
plied Biosystems, Foster City, Calif.) amplification to target 
the additional of 1 ng of total human DNA in 10 µL according 
to recommendations from the supplier (23). According to the 
supplier, an Yfiler™ amplification targeting the addition of 1 
to calculate the amount of DNA sample to add to an Identi-
filer™ (Applied Biosystems, Foster City, Calif.) amplifica-
tion to target the addition ofl ng of total human DNA in 10 µL 
according to recommendations from the supplier (24). 
According to the kit supplier, an Identifiler amplification 
targeting the addition of0.5 to 1.25 ng/µL would yield DNA 
profiling results with peak heights of between 1000 to 3000 
RFU. The rationale was that if the higher quantification esti-
mate was more valid than the lower quantification estimate 
between the two estimates, then the resulting Identifiler™ 
profiling results would appear to be over-amplified (peaks 30 
above 3000 RFU). And, conversely, if the lower quantifica-
tion estimate was more valid than the higher quantification 
estimate between the two estimates, then the resulting Iden-
tifiler™ profiling results would appear to be under-amplified 
(peaks below 1000 RFU). The dilution scheme and best esti- 35 
mate results obtained from the Identifiler™ profiling of the 
average of the total human DNA quantification results from 
the improved multiplex assay and Quantifiler® are presented 
25 ng/µL would yield DNA profiling results with peak heights of 
between 1000 to 3000 RFU. The rationale was that if the 
in Table 8. Six out of eleven times (55%), the improved 
multiplex estimate appears to provide the better estimate of 40 
successful DNA profiling. The ability of the improved mul-
tiplex assay to provide accurate quantitation of male-only 
DNA in forensic samples by use of the results from the SRY 
amplicon was then assessed. The concentration of male-only 
DNA in eight of the actual casework samples presented in 45 
Table 8 was further evaluated by comparing the quantification 
values determined by the SRY amplicon of the improved 
multiplex assay to the quantification values determined dur-
ing Quantifiler® Y analysis (see Table 9). 
higher quantification estimate was more valid than the lower 
quantification estimate between the two estimates, then the 
resulting Yfiler™ haplotype would appear to be over-ampli-
fied (peaks above 3000 RFU). And, conversely, if the lower 
quantification estimate was more valid than the higher quan-
tification estimate between the two estimates, then the result-
ing Yfiler™ haplotype would appear to be under-amplified 
(peaks below 1000 RFU). The dilution scheme and best esti-
mate results obtained from Yfiler™ haplotyping of the aver-
age of the male-only DNA quantification results from the 
improved multiplex assay and Quantifiler® Y are presented in 
Table 9. Five out of eight times (62%), the improved multi-
plex assay appears to provide the better estimate for success-
ful YSTR haplotyping. 
Theoretically, in a pure male DNA samples, the SRY male-
only DNA quantity estimate should be the same as the total 
human DNA quantity estimate. However, a common stochas-
tic effect of PCR amplification is that smaller amplicons are 
amplified more frequently than larger amplicons. This effect 
will cause an elevation of the peak height RFU estimation 
from a smaller amplicon post-amplification than the peak 
height RFU estimation from a larger amplicon post-amplifi-
cation. This disparity probably occurs at a ratio similar to the 
TABLE9 
Dilution scheme for Yfiler profiling based on average quantification 
values estimated by IMA and Quantifiler for 8 actual casework sam12les 
IMA Estimate Quantifiler Mean(µ) 
of Male- Y Estimate Estimate of pg of Most 
Sample Only of Male- Male-Only Dilution DNA in Accurate 
Number DNA Only DNA DNA Recipe in TE l0uL Identifiler EP Estimate 
4225 2936 3581 in 34 1023 over-amplified IMA 
2 474 459 467 3 in 11 1000 over-amplified IMA 
3 2025 2125 2075 in 19 1038 over-amplified Quantifiler 
4 66 80 73 730 slightly under- IMA 
amplified 
5 554 935 745 2 in 12 1064 over-amplified Quantifiler 
6 462 912 687 2 in 11 1057 over-amplified Quantifiler 
7 613 181 397 3 in 8 1083 over-amplified IMA 
8 602 504 553 2 in 9 1005 over-amplified IMA 
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but it does not appear that the Amelogenin Y or SRY ampli-
cons will give false male-DNA results for forensic samples. 
The improved multiplex assay detects "maleness" in a redun-
dant fail-safe way. The SRY amplicon can easily detect 125 
pg/µL of male DNA in a sample with up to 400 times more 
female DNA present in the sample. There appears to be no 
limit to the ability of the SRY amplicon to present itself in an 
unlimited quantity of female DNA as long as 125 pg/µL of 
male DNA resides in the sample. Amelogenin Y provides a 
redundant indication of maleness down to about a 1:20 ratio 
of male to female DNA or stain material. In certain population 
groups, males may exhibit unusually high levels ofY chro-
mosomal mutation that may obliterate the primer binding site 
fortheAmelogenin primer set in this assay (C, I, H). For these 
males, the improved multiplex assay would still be able to 
detect the presence of the SRY amplicon as an indicator of 
maleness. Qualitatively, the presence of male DNA could be 
detected by either the Amelogenin Y amplicon or the SRY 
amplicon although these amplicons have varying sensitivities 
of detection in mixtures. We chose to base our male-only 
DNA quantification upon the SRY amplicon because of its 
increased sensitivity as a haploid amplicon with no female 
counterpart to cause stochastic interference. However, in the 
presence of an SRY primer-binding mutation theAmelogenin 
Y amplicon can be quantified by using the Amelogenin X 
standard curve to estimate the picogram amount of DNA in 
the single Amelogenin Y amplicon and multiplying this value 
times two (Y + Y) to estimate the total of male-only DNA in a 
sample regardless of a pure or mixed sample and regardless of 
the amount ofAmelogeninX amplicon. This method of deter-
mining male-only DNA quantity in a sample is just a less 
sensitive method for determining male-only DNA in mixed 
samples. 
The improved multiplex assay is very sensitive in detecting 
allele peak height imbalance seen between diploid alleles 
amplified by one primer set. Normal peak height imbalance 
can easily have an imbalance ratio of 60% to 40% or, in other 
words, a larger peak to smaller peak ratio of 1.5 (25). Ifa DNA 
sample is amplified at specific time points while it is under- 5 
going DNA degradation, amplicons will be seen to arise from 
smaller pieces of template DNA more frequently during a 
time period ofDNase I digestion than amplicons arising from 
larger-sized template DNA. In partially degraded DNA 
samples, this disparity between the fluorescence of a smaller 10 
amplicon post-amplification and the fluorescence of a larger 
amplicon post-amplification will be seen during the specific 
time periods when larger template DNA would be too 
degraded to function as templates during amplification, but 
smaller DNA templates would still be able to function as 15 
templates during amplification. With these factors in mind, 
the addition of the SRY primer set to the improved multiplex 
assay appears to be able to assess degradation in pure male 
DNA samples. FIG. 12a demonstrates the decreasing 
amounts of peak-height RFU obtained in a male DNA sample 20 
subjected to DNase I enzymatic digestion over increasing 
periods of digestion time. The SRY amplicon is smaller than 
the Amelogenin X amplicon and Amelogenin Y amplicon by 
approximately 100 basepairs and appears to suffer the effects 
ofDNase I digestion much later than do the other amplicons, 25 
as expected. The estimated picograms of male-only DNA 
derived from comparison of the SRY amplicon to the male-
only SRY standard curve can be compared to the estimated 
picograms of total human DNA derived from the sum of the 
fluorescence of the Amelogenin X andAmelogenin Y ampli- 30 
cons compared to the total human X standard curve. As stated 
earlier, in a pure male sample, these estimates should be 
within a ratio of around 1.5 if stochastic effects are taken into 
account. But, if the male-only DNA estimate for each time 
point based on the SRY amplicon is truly within a degraded 
DNA sample, then the ratio of the male-only DNA estimate 
(SRY peak height RFU) to the total human DNA estimate 
(Amelogenin X+Amelogenin Y peak height RFU) should 
begin to significantly increase. A ratio of 3.00 would repre-
sent a ratio of male-only DNA to total human DNA of75% to 
25%. A graph of this ratio over increasing periods of digestion 
time is presented in FIG. 12b. Note that at time zero of 
digestion, the ratio of the SRY peak height RFU to theAmelo-
genin X+Y peak height RFU is between 1.0 and 1.5, as 
expected. After time zero, each area in the graphed ratio rising 
above 3.00 represents a time period of digestion in which 
SRY peak height RFU was 75% or greater than the Amelo-
genin X+ Y peak height RFU. The time points when the 
graphed ratios rise above 3.00 indicate that the sample had 
degraded to the point that it contained mostly DNA fragments 
that were larger than 100 basepairs but shorter than 200 base-
35 human and male-only DNA in samples. We have determined 
that the limit of detection for the improved multiplex assay 
must lie just below an input DNA of 63 pg. In FIG. 13 we 
graph the amount of DNA estimated within a sample against 
the amounts of DNA sample at each estimate that would need 
pairs. 
Discussion 
The improved assay that we validate in this study fulfills all 
of the criteria desirable in an ideal quantification method. The 
improved multiplex assay successfully detects chemical 
inhibitors of DNA amplification indicating that additional 
purification of the DNA sample will be needed before suc-
cessful DNA profiling can be performed. The improved assay 
is human specific. When the human-specificity of the 
improved multiplex assay is compared to three types of non-
human primates, only the Amelogenin X amplicon is pro-
duced with any consequence. The male non-human primate 
sample did not exhibit Amelogenin Y amplicon production, 
nor did it exhibit SRY amplicon production. The improved 
multiplex assay may give false positive results for Ameloge-
nin X in the presence of non-human primate DNA material, 
40 to be input into anAmpFlSTR® Identifiler™ PCR reaction or 
an AmpFlSTR® Yfiler™ PCR reaction. The AmpFlSTR® 
Identifiler™ PCR Amplification Kit manual says that the 
analyst should target the addition of 0.5 to 1.25 ng in a total 
volume of 10 µL. This corresponds to the addition of 10 µL of 
45 a 50-125 pg/µL DNA sample. The AmpFlSTR® Yfiler™ 
PCR Amplification Kit manual says that the analyst should 
target the addition of 1 ng in a total volume of 10 µL. This 
corresponds to the addition of 10 µL of a 100 pg/µL DNA 
sample. The AmpFlSTR® MiniFiler™ PCR Amplification 
50 Kit manual says that the analyst should target the addition of 
0.5-0.75 ng in a total volume ofl0 µL (29). This corresponds 
to the addition of 10 µL of a 50-7 5 pg/µL DNA sample. As 
demonstrated by the graph in FIG.13, if the amount of DNA 
estimated in the sample was ~ 100 pg/µL, then 10 µL of that 
55 sample would need to be amplified to target the ideal input 
DNA for either Identifiler™ or Yfiler™ DNA testing even 
with a quantification method having a CV of 30% ( see upper 
and lower bound lines in FIG. 13). 
Moreover, the sensitivity and performance of the improved 
60 multiplex assay is very relevant. Quantification methods are 
more desirable if they can best predict the success of later 
DNA profiling of a particular forensic evidence sample by 
having a dynamic range that overlaps the optimal DNA con-
centration range of later DNA-profiling procedures. The 
65 improved multiplex assay has the same amplification param-
eters and diploid versus haploid stochastic efficiencies as the 
commercially available genomic DNA profiling kits. The 
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Amelogenin X and Amelogenin Y amplicons amplify within 
the size range and stochastic efficiency of the Identifiler™ 
DNA profiling kit. The ratio of Amelogenin X to Amelogenin 
Yin mixed samples very accurately mirrors the amplification 
ratios that will be seen between the major and minor, male and 
female contributors when the mixture is genomically DNA 
profiled. The SRY amplicon amplifies within the size range 
and stochastic efficiency of the commercially available male 
Y-chromosome DNA haplotyping kits such as Y-filer (Ap-
plied Biosystems, Foster City, Calif.). The SRY amplicon in 
the improved multiplex assay is 111 nucleotides in length. 
The lengths of the haplotypes profiled by Y-STR profiling are 
100-300 nucleotides in length. The Quantifiler® Y kit bases 
48 
lysts performing the improved multiplex assay perform tasks 
that would be easily automated. The generation of standard 
curves and sample dilutions is completely amenable to auto-
mation. Because the improved multiplex assay can both gen-
5 der-type and quantitate DNA samples containing any male 
DNA, the improved multiplex assay can serve as a qualitative 
screening method. This, coupled with automation and a low 
cost, would potentially allow for a high volume and low cost 
ability to screen large amounts of evidentiary items such as 
10 the burgeoning backlog of sexual assault evidence collection 
kits and other evidence that some forensic laboratories are 
currently experiencing. 
its estimation of male-only DNA upon the amplification of an 15 
SRY amplicon only 60 nucleotides in length. This shorter 
SRY amplicon made the Quantifiler® Y assay more sensitive 
TABLE 10 
Exemplary dilution schemes 
Calculated Total Human DNA in pg/uL 
in detecting male DNA in a sample, but later profiling of these 
samples would not yield successful Yfiler™ haplotyping 
results (personal communication with anApplied Biosystems 20 
representative) The shorter SRY amplicon was a good pre-
dictor of male DNA in a sample, but was not a good predictor 
<63 
63 
125 
250 
Null 
<63 
63 
125 
250 
1:l0Dilution 1:100 Dilution 1 :200 Dilution 
Too Dilute Too Dilute Too Dilute 
Too Dilute Too Dilute Too Dilute 
Too Dilute Too Dilute Too Dilute 
Too Dilute Too Dilute Too Dilute 
of successful YSTR testing (30). The Quantifiler® Y Kit is 
undergoing modification to adjust the SRY primers so that the 
SRY amplicon is a longer length that approximates the 100- 25 
300 nucleotide amplified haplotypes of the Yfiler™ PCR 
Amplification Kit (30). We believe that the SRY amplicon in 
our improved multiplex assay is not only a sensitive detector 
500 
750 
1,000 
1,500 
2,000 
2,500 
5,000 
500 
truncated 
truncated 
truncated 
truncated 
truncated 
truncated 
<63 Too Dilute Too Dilute 
75 Too Dilute Too Dilute 
100 Too Dilute Too Dilute 
150 Too Dilute Too Dilute 
200 Too Dilute Too Dilute 
250 Too Dilute Too Dilute 
500 <63 Too Dilute 
of male DNA in a sample, it is also an accurate predictor of truncated truncated 100 <63 
successful YSTR haplotyping (see Tables 7, 8, and 9). 30 
10,000 
15,000 truncated truncated 150 75 
The improved multiplex assay has been determined by our 
analyses to have a dynamic range of 63 pg to 500 pg detection 
20,000 
30,000 
truncated truncated 
truncated truncated 
truncated truncated 
200 100 
300 150 
400 200 
of input DNA in 1 µL. When coupled with the ability to dilute 
input DNA the dynamic range becomes unlimited (see Table 35 
10). Within only four dilutions, a sample containing any-
where from 63 pg/µL DNA to 100,000 pg/µL DNA can be 
quantified using the improved multiplex assay-every pos-
sible DNA quantitation result can be anticipated to fall within 
one of the dilution schemes in the Table 10. The need for 40 
40,000 
50,000 
60,000 
70,000 
80,000 
90,000 
100,000 
truncated 
truncated 
truncated 
truncated 
truncated 
truncated 
truncated 500 250 
truncated truncated 300 
truncated truncated 350 
truncated truncated 400 
truncated truncated 450 
truncated truncated 500 
dilution necessitates repeat sample analysis, which can 
become costly and time consuming, but the improved multi-
plex assay is extremely low cost, fast, hands-free, and low 
maintenance. Current DNA profiling technology relies upon 
a basic PCR amplification followed by CEFD analysis. The 
improved multiplex assay relies upon these same two tech-
nologies. For this reason, the assay is extremely cheap to 
initiate at a DNA profiling laboratory and additional space is 
not required. No new instrumentation is needed. Analysts do 
not have to spend time training for the proper usage of new 
equipment and learning new technology. Validation is very 
straight-forward. Because virtually no new reagents are 
required for this assay, time and resources are not spent upon 
quality assurance practices and quality control activities. The 
original assay amplification cycle has been optimized and 
shortened. The procedure has been validated in this study 
using a thermo-stable DNA polymerase that costs approxi-
mately thirty cents a reaction. The three primer sets can be 
ordered online and manufactured for less than sixty cents. 
This translates into a set of reagents that cost less than one 
dollar per sample. DNA samples requiring quantification can 
be amplified in less than an hour and forty-five minutes. 
Sample analysis takes twenty-one minutes per sample on a 
ABI Prizm® 310 Genetic Analyzer, but a multicapillary 
CEFD device or a DNA chip device could dramatically 
decrease the time involved to perform the improved multiplex 
assay. The improved multiplex assay is very hands-off. Ana 
Current research in this laboratory is focused upon the 
ability of the improved multiplex assay to detect DNA deg-
radation levels in some samples. From FIG. 12b it appears 
that the improved multiplex assay can detect the effects of 
45 degradation. However, because the SRY amplicon is critical 
in assessing the level of degradation, degradation can only be 
assessed for the male component of DNA samples. We are 
intrigued that no other quantitation method provides infor-
mation diagnosing the level of DNA degradation or average 
50 DNA fragment length within a sample save the yield gel. If 
DNA degradation levels that preclude the success of regular 
DNA testing procedures can be determined in a DNA sample, 
then an early decision can be made to use DNA testing pro-
cedures that are more successful on degraded samples such as 
55 the newly introducedAmpFlSTR® MiniFiler™ PCRAmpli-
ficationKit (Applied Biosystems, Foster City, Calif.). Further 
improvement of the improved multiplex assay may be 
achieved by addition of a 100 bp amplicon that can estimate 
60 total human DNA concentration for the detection of degrada-
tion in male, female, and mixed samples. We are also inter-
ested in the effect of an undiagnosed high percent CV for 
detecting peak height RFU among CEFD devices utilized in 
forensic mixture profiling. We are interested in the effect of 
65 high quantitative percent CV values on the accuracy of deter-
mining major and minor contributors to mixtures. To the best 
of our knowledge, the CEFD device was designed for accu 
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rately size-calling DNA fragments (26). Determining the per-
cent CV for a CEFD device's size-calling ability is a routine 
quality control and instrumental validation activity for labo-
ratories performing DNA profiling with CEFD devices. 
Determining the percent CV of a CEFD device for accurately 5 
quantifying any particular DNA fragment has not, to the best 
of our knowledge, been adequately addressed by the forensic 
community, although the quantitative use of CEFD has been 
published (27, 28). In FIG. 15, the percent CV for any par-
ticular CEFD device to detect peak-height fluorescence 10 
within a single DNA sample did not appear to be very repro-
ducible for some instruments. The percent CV for peak-
height fluorescence ranged from 6.05% to 46.17%. And, as 
expected, the percent CV for the detection of peak-height 
fluorescence has no correlation with the percent CV of the 15 
same instrument for size-calling ability. In other words, even 
if a CEFD device has a very low CV for size-calling, it may 
have a very high CV for detecting peak height RFU and we 
were quite unaware of this fact until this study. 
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<160> NUMBER OF SEQ ID NOS, 12 
<210> SEQ ID NO 1 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
US 8,153,372 B2 
SEQUENCE LISTING 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 1 
acctcatcct gggcaccctg g 
<210> SEQ ID NO 2 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 2 
aggcttgagg ccaaccatca g 
<210> SEQ ID NO 3 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 3 
acgaaagcca cacactcaag aat 
<210> SEQ ID NO 4 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 4 
ctacagcttt gtccagtggc 
<210> SEQ ID NO 5 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 5 
aaggtggtaa acctgacgtt g 
<210> SEQ ID NO 6 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 6 
ttcatcaggt gcatcttctt g 
<210> SEQ ID NO 7 
<211> LENGTH, 21 
<212> TYPE, DNA 
52 
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-continued 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 7 
acctcatcct gggcaccctg g 
<210> SEQ ID NO 8 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 8 
aggcttgagg ccaaccatca g 
<210> SEQ ID NO 9 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 9 
acgaaagcca cacactcaag aat 
<210> SEQ ID NO 10 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 10 
ctacagcttt gtccagtggc 
<210> SEQ ID NO 11 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 11 
aaggtggtaa acctgacgtt g 
<210> SEQ ID NO 12 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 12 
ttcatcaggt gcatcttctt g 
We claim: 
1. A method for determining, in a sample, using a single 60 
multiplex PCR reaction, each of: a quantity of genomic DNA 
from a male donor and a quantity of genomic DNA from a 
female donor, a ratio between said quantity of genomic DNA 
from said male donor and said quantity of genomic DNA 65 
from said female donor, extent of genomic DNA degradation, 
and presence of PCR inhibitors, comprising the steps of 
21 
21 
23 
20 
21 
21 
i) creating a reaction mix by combining an aliquot of said 
sample and DNA encoding a non-human reporter gene; 
ii) amplifying said reaction mix in a single multiplex PCR 
reaction using a plurality of primer sets comprising: 
a) a first primer set comprising synthetic oligonucleotide 
primers directed against human male and female amelo-
genin genetic loci; 
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b) a second primer set comprising synthetic oligonucle-
otide primers directed against a human Y-chromosome 
specific gene or a human X-chromosome specific gene, 
or both; 
wherein amplicons produced from said human Y-chromo- 5 
some specific gene and said human X-chromosome spe-
cific gene are shorter than amplicons produced from said 
human male and female amelogenin genetic loci; and 
c) a third primer set comprising synthetic oligonucleotide 
... primers_ directed against said non-human reporter gene; 10 
111) detectmg PCR amplicons produced in said step of 
amplifying; and 
iv) making an assessment of: 
a) said quantity of genomic DNA from a male donor and 
said quantity of genomic DNA from a female donor 15 
b) said ratio between said quantity of genomic DNA 
from said male donor and said quantity of genomic 
DNA from said female donor, 
c) sa)d extent of genomic DNA degradation, and 
d) said presence of PCR inhibitors in said sample based 20 
on quantities of non-human PCR amplicons detected 
in said detecting step, 
wherein said step of making an assessment of said extent of 
genomic degradation includes a step of 
i. calculating a ratio of: 
PCR amplicons produced by amplifying said human 
Y-chromosome specific gene and said human male 
amelogenin genetic locus; and 
25 
PCR amplicons produced by amplifying said human 
X-chromosome specific gene and said human female 30 
amelogenin genetic locus. 
2. The method of claim 1, wherein said step of making an 
assessment determines gender of a donor of said genomic 
DNA based on the presence or absence of amplicons pro-
duced by amplification of said human Y-chromosome specific 35 
gene and said hui:nan X-chromosome specific gene being 
shorter than amphcons produced by amplification of said 
human male and female amelogenin loci. 
3. The method of claim 1, wherein said Y-chromosome 
specific gene is Sex-Determining RegionY (SRY). 
4. The method of claim 1, wherein said non-human reporter 
gene is a luciferase gene. 
40 
_5. The method of claim 1, wherein one of said synthetic 
ol~gonucleotide primers in said first primer set, said second 
pnmer set and said third primer set includes a detectable 45 
label. 
6. The method of claim 5, wherein said detectable label is 
fluorescent. 
7. !he ~ethod_ of claim 1, wherein said step of detecting 
amphcons 1s earned out using capillary electrophoresis. 50 
8. The method of claim 1, wherein said sample is a forensic 
sample. 
56 
_9. T~e i:nethod of claim 1, further comprising the step of, if 
said rat10 1s between 1 and 1.5, concluding that said genomic 
DNA in said sample is not degraded. 
10. The method of claim 1, wherein said X-chromosome 
specific gene is hypoxanthine-guanine phosphoribosyl trans-
ferase (HGPRT). 
11. A method for determining an extent of genomic DNA 
degradation in a sample, using a single multiplex PCR reac-
tion, comprising the steps of 
i) creating a reaction mix comprising said sample; 
ii) amplifying said reaction mix in a single multiplex PCR 
reaction using a plurality of primer sets comprising: 
a) a first primer set comprising synthetic oligonucleotide 
primers directed against a first genetic locus on a 
chromosome; 
b) a second primer set comprising synthetic oligonucle-
otide primers directed against a second genetic locus 
on said chromosome; wherein amplicons produced 
from said second genetic locus are shorter than ampli-
cons produced from said first genetic locus· and 
iii) detecting PCR amplicons produced in said step of 
amplifying; and 
iv) making an assessment of said extent of genomic DNA 
degradation by calculating a ratio of: 
PCR amplicons produced by amplifying said first 
genetic locus; and 
PCR amplicons produced by amplifying said second 
genetic locus. 
. 12_. The i:net~od of claim 11, further comprising the step of, 
1f said rat10 1s between 1 and 1.5, concluding that said 
genomic DNA in said sample is not degraded. 
. 1~. Th~ ~ethod of claim 11, further comprising the step of, 
1f said rat10 1s 3 or greater, concluding that said genomic DNA 
in said sample is degraded. 
. 14. The method of claim 11, wherein said first genetic locus 
1s a human amelogenin locus. 
15. !he method of claim 11, wherein said second genetic 
locus 1s a human Y-chromosome specific gene or a human 
X-chromosome specific gene. 
16. The method of claim 11, wherein said reaction mix 
furthe~ co~prises DNA encoding a reporter gene, and 
wherem said method further comprises the steps of: 
amplifying said reporter gene using a third primer set com-
prising synthetic oligonucleotide primers directed 
against said reporter gene; and, 
determining the presence or absence of PCR inhibitors in 
said sample based on amplification of said reporter gene. 
17. The method of claim 11, wherein said chromosome is 
the Y chromosome. 
18. The method of claim 11, wherein said first genetic locus 
is SRY and said second genetic locus is amelogenin. 
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